CIGNA GROUP, 10-Q filed on 5/2/2025
Quarterly Report
v3.25.1
Cover Page - shares
 3 Months Ended
Mar. 31, 2025
Apr. 25, 2025
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Transition Report false  
Entity File Number 001-38769  
Entity Registrant Name The Cigna Group  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 82-4991898  
Entity Address, Address Line One 900 Cottage Grove Road  
Entity Address, City or Town Bloomfield  
Entity Address, State or Province CT  
Entity Address, Postal Zip Code 06002  
City Area Code 860  
Local Phone Number 226-6000  
Title of 12(b) Security Common Stock, Par Value $0.01  
Trading Symbol CI  
Security Exchange Name NYSE  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   267,142,597
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2025  
Current Fiscal Year End Date --12-31  
Amendment Flag false  
Entity Central Index Key 0001739940  
Document Period End Date Mar. 31, 2025  
v3.25.1
Consolidated Statements of Income - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Revenues    
Premiums $ 12,736 $ 11,603
Net investment income 238 290
TOTAL REVENUES 65,502 57,255
Benefits and expenses    
Pharmacy and other service costs 48,398 41,431
Medical costs and other benefit expenses 10,498 9,440
Selling, general and administrative expenses 4,213 3,705
Amortization of acquired intangible assets 422 423
TOTAL BENEFITS AND EXPENSES 63,531 54,999
Income from operations 1,971 2,256
Interest expense and other (362) (322)
Gain (loss) on sale of businesses 41 (19)
Net investment losses (2) (1,836)
Income before income taxes 1,648 79
TOTAL INCOME TAXES 239 291
Net income (loss) 1,409 (212)
Less: Net income attributable to noncontrolling interests 86 65
SHAREHOLDERS' NET INCOME (LOSS) $ 1,323 $ (277)
Shareholders' net income (loss) per share    
Basic (in dollars per share) $ 4.88 $ (0.97)
Diluted (in dollars per share) $ 4.85 $ (0.97)
Pharmacy revenues    
Revenues    
Revenue from contract with customer $ 48,633 $ 42,036
Fees and other revenues    
Revenues    
Revenue from contract with customer $ 3,895 $ 3,326
v3.25.1
Consolidated Statements of Comprehensive Income - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Statement of Comprehensive Income [Abstract]    
Net (loss) income $ 1,409 $ (212)
Other comprehensive income (loss), net of tax    
Net unrealized (depreciation) appreciation on securities and derivatives (100) 121
Net long-duration insurance and contractholder liabilities measurement adjustments (168) (560)
Net translation gains (losses) on foreign currencies 13 (26)
Postretirement benefits liability adjustment 6 5
Other comprehensive income (loss) (249) (460)
Total comprehensive income (loss) 1,160 (672)
Less: Net income attributable to noncontrolling interests 86 65
SHAREHOLDERS' COMPREHENSIVE INCOME (LOSS) $ 1,074 $ (737)
v3.25.1
Consolidated Balance Sheets - USD ($)
$ in Millions
Mar. 31, 2025
Dec. 31, 2024
Assets    
Cash and cash equivalents $ 8,334 $ 7,550
Investments 727 665
Accounts receivable, net 26,929 24,227
Inventories 5,176 6,692
Other current assets 2,389 2,732
Assets of businesses held for sale 0 7,004
Total current assets 43,555 48,870
Long-term investments 15,350 15,128
Reinsurance recoverables 4,375 4,378
Property and equipment 3,681 3,654
Goodwill 44,372 44,370
Other intangible assets 29,045 29,417
Other assets 3,003 2,786
Separate account assets 7,277 7,278
TOTAL ASSETS 150,658 155,881
Liabilities    
Current insurance and contractholder liabilities 5,984 5,388
Pharmacy and other service costs payable 28,600 28,465
Accounts payable 9,136 9,294
Accrued expenses and other liabilities 8,032 9,387
Short-term debt 3,993 3,035
Liabilities of businesses held for sale 0 2,410
Total current liabilities 55,745 57,979
Non-current insurance and contractholder liabilities 10,309 10,254
Deferred tax liabilities, net 6,879 6,975
Other non-current liabilities 3,579 3,215
Long-term debt 26,455 28,937
Separate account liabilities 7,277 7,278
TOTAL LIABILITIES 110,244 114,638
Contingencies — Note 16
Shareholders' equity    
Common stock [1] 4 4
Additional paid-in capital 31,443 31,288
Accumulated other comprehensive loss (2,590) (2,341)
Retained earnings 44,434 43,519
Less: Treasury stock, at cost (33,065) (31,437)
TOTAL SHAREHOLDERS' EQUITY 40,226 41,033
Noncontrolling interests 188 210
Total equity 40,414 41,243
Total liabilities and equity $ 150,658 $ 155,881
[1] Par value per share, $0.01; shares issued, 404 million as of March 31, 2025 and 403 million as of December 31, 2024; authorized shares, 600 million.
v3.25.1
Consolidated Balance Sheets (Parenthetical) - $ / shares
Mar. 31, 2025
Dec. 31, 2024
Statement of Financial Position [Abstract]    
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares issued (in shares) 404,000,000 403,000,000
Common stock, shares authorized (in shares) 600,000,000 600,000,000
v3.25.1
Consolidated Statements of Changes in Total Equity - USD ($)
$ in Millions
Total
Shareholders' Equity
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive (Loss)
Retained Earnings
Treasury Stock
Other Non- controlling Interests
Balance at Dec. 31, 2023 $ 46,244 $ 46,223 $ 4 $ 30,669 $ (1,864) $ 41,652 $ (24,238) $ 21
Changes in Total Equity                
Effect of issuing stock for employee benefit plans 149 149   263     (114)  
Other comprehensive income (loss) (460) (460)     (460)      
Net (loss) income (212) (277)       (277)   65
Common dividends declared (397) (397)       (397)    
Repurchase of common stock (4,057) (4,057)   (640)     (3,417)  
Other transactions impacting noncontrolling interests 83 0   0       83
Balance at Mar. 31, 2024 41,350 41,181 4 30,292 (2,324) 40,978 (27,769) 169
Balance at Dec. 31, 2023 107              
Change in Redeemable Noncontrolling Interests                
Other comprehensive loss 0              
Net (loss) income 0              
Other transactions impacting noncontrolling interests (107)              
Balance at Mar. 31, 2024 0              
Balance at Dec. 31, 2024 41,243 41,033 4 31,288 (2,341) 43,519 (31,437) 210
Changes in Total Equity                
Effect of issuing stock for employee benefit plans 48 48   155     (107)  
Other comprehensive income (loss) (249) (249)     (249)      
Net (loss) income 1,409 1,323       1,323   86
Common dividends declared (408) (408)       (408)    
Repurchase of common stock (1,521) (1,521)   0     (1,521)  
Other transactions impacting noncontrolling interests (108) 0   0       (108)
Balance at Mar. 31, 2025 40,414 $ 40,226 $ 4 $ 31,443 $ (2,590) $ 44,434 $ (33,065) $ 188
Balance at Dec. 31, 2024 0              
Change in Redeemable Noncontrolling Interests                
Other comprehensive loss 0              
Net (loss) income 0              
Other transactions impacting noncontrolling interests 0              
Balance at Mar. 31, 2025 $ 0              
v3.25.1
Consolidated Statements of Changes in Total Equity (Parenthetical) - $ / shares
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Statement of Stockholders' Equity [Abstract]    
Common dividends declared (in dollars per share) $ 1.51 $ 1.40
v3.25.1
Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Cash Flows from Operating Activities    
Net (loss) income $ 1,409 $ (212)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:    
Depreciation and amortization 674 741
Investment losses, net 2 1,836
Deferred income tax benefit (216) (102)
(Gain) loss on sale of businesses (41) 19
Net changes in assets and liabilities, net of non-operating effects:    
Accounts receivable, net (2,205) (2,687)
Inventories 1,517 1,015
Reinsurance recoverable and Other assets (219) 68
Insurance liabilities 1,778 532
Pharmacy and other service costs payable 135 4,637
Accounts payable and Accrued expenses and other liabilities (1,174) (1,068)
Other, net 260 61
NET CASH PROVIDED BY OPERATING ACTIVITIES 1,920 4,840
Proceeds from investments sold:    
Debt securities and equity securities 94 268
Investment maturities and repayments:    
Debt securities and equity securities 222 179
Commercial mortgage loans 85 4
Other sales, maturities and repayments (primarily short-term and other long-term investments) 331 272
Investments purchased or originated:    
Debt securities and equity securities (952) (180)
Commercial mortgage loans (34) (32)
Other (primarily short-term and other long-term investments) (475) (594)
Property and equipment purchases, net (327) (300)
Divestitures, net of cash sold 2,346 0
Renewable energy tax credit equity investments (92) (104)
Other, net (1) (8)
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES 1,197 (495)
Cash Flows from Financing Activities    
Deposits and interest credited to contractholder deposit funds 36 43
Withdrawals and benefit payments from contractholder deposit funds (64) (65)
Net change in short-term debt (891) (364)
Repayment of long-term debt (700) (2,210)
Net proceeds on issuance of long-term debt 0 4,462
Repurchase of common stock (1,508) (4,022)
Issuance of common stock 69 181
Common stock dividend paid (412) (401)
Other, net (211) (153)
NET CASH USED IN FINANCING ACTIVITIES (3,681) (2,529)
Effect of foreign currency rate changes on cash, cash equivalents and restricted cash 9 (9)
Net (decrease) increase in cash, cash equivalents and restricted cash (555) 1,807
Cash, cash equivalents and restricted cash January 1, including held for sale assets [1] 8,931 8,337
Cash, cash equivalents and restricted cash December 31, including held for sale assets [1] 8,376 10,144
Cash and cash equivalents reclassified to assets of businesses held for sale 0 (1,660)
Cash, cash equivalents and restricted cash and cash equivalents December 31, [1] 8,376 8,484
Supplemental Disclosure of Cash Information:    
Income taxes paid, net of refunds 140 110
Interest paid $ 379 $ 336
[1] Restricted cash and cash equivalents were reported in other long-term investments.
v3.25.1
Description of Business
 3 Months Ended
Mar. 31, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Description of Business
Note 1 – Description of Business
The Cigna Group®, together with its subsidiaries (either individually or collectively referred to as the "Company," "we," "us" or "our"), is a global health company committed to creating a better future for every individual and every community. We relentlessly challenge ourselves to partner and innovate solutions for better health. Powered by our people and our brands, we advance our mission to improve the health and vitality of those we serve.

Our subsidiaries offer a differentiated set of pharmacy, medical, behavioral, dental, and related products and services. The majority of these products and services are offered through employers and other entities, such as governmental and nongovernmental organizations, unions and associations. Cigna Healthcare® also offers health and dental insurance products to individuals in the United States and select international markets. In addition to these operations, The Cigna Group also has certain run-off operations.

A full description of our segments follows:
The Evernorth Health Services® reportable segment includes the Pharmacy Benefit Services and the Specialty and Care Services operating segments, which provide independent and coordinated health solutions and capabilities to enable the health care system to work better and help people live richer, healthier lives.

Pharmacy Benefit Services drives high-quality, cost-effective pharmacy care through various services, such as drug claim adjudication, retail pharmacy network administration, benefit design consultation, drug utilization review, drug formulary management and access to our home delivery pharmacy. Specialty and Care Services provides specialty drugs for the treatment of complex and rare diseases, specialty distribution of pharmaceuticals and medical supplies, as well as clinical programs to help our clients drive better whole-person health outcomes through care services.

The Cigna Healthcare reportable segment includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical and coordinated solutions to clients and customers. U.S. Healthcare provides medical plans and other benefits and solutions for insured clients, self-insured clients and individual health insurance plans. International Health provides health care solutions in our international markets, as well as health care benefits for globally mobile individuals and employees of multinational organizations. U.S. Healthcare also included the Medicare Advantage and related businesses until the divestiture of such businesses to Health Care Services Corporation ("HCSC") on March 19, 2025 (see Note 5 to the Consolidated Financial Statements for further information).
Other Operations comprises the remainder of our business operations, which includes certain continuing (corporate-owned life insurance ("COLI")), run-off and other non-strategic businesses. Our run-off businesses include the (i) variable annuity reinsurance business that was effectively exited through reinsurance with Berkshire Hathaway Life Insurance Company of Nebraska ("Berkshire") in 2013, (ii) settlement annuity business, and (iii) individual life insurance and annuity and retirement benefits businesses, which were sold through reinsurance agreements.
Corporate reflects amounts not allocated to operating segments, including net interest expense (defined as interest on corporate financing less net investment income on investments not supporting segment and other operations), certain litigation matters, expense associated with our frozen pension plans, charitable contributions, operating severance, certain overhead and enterprise-wide project costs, and eliminations for products and services sold between segments.
v3.25.1
Summary of Significant Accounting Policies
 3 Months Ended
Mar. 31, 2025
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies
Note 2 – Summary of Significant Accounting Policies    
Basis of Presentation
The Consolidated Financial Statements include the accounts of The Cigna Group and its consolidated subsidiaries. Intercompany transactions and accounts have been eliminated in consolidation. These Consolidated Financial Statements were prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP"). Certain amounts in the Consolidated Statements of Cash Flows have been reclassified to conform to current year presentation and did not have a significant impact on our Consolidated Financial Statements.

Amounts recorded in the Consolidated Financial Statements necessarily reflect management's estimates and assumptions about medical costs, investment, tax and receivable valuations, interest rates, and other factors. Significant estimates are discussed throughout these Notes; however, actual results could differ from those estimates. The impact of a change in estimate is generally included in earnings in the period of adjustment.
These interim Consolidated Financial Statements are unaudited but include all adjustments (including normal recurring adjustments) necessary, in the opinion of management, for a fair statement of financial position and results of operations for the periods reported.
The interim Consolidated Financial Statements and Notes should be read in conjunction with the Consolidated Financial Statements and Notes included in the 2024 Annual Report on Form 10-K ("2024 Form 10-K"). The Company has not included certain footnote disclosures that would substantially duplicate the disclosures contained in its 2024 Form 10-K, unless the information in those disclosures materially changed or is required by GAAP. The preparation of interim Consolidated Financial Statements necessarily relies heavily on estimates. This and other factors, including the seasonal nature of portions of the health care and related benefits business, as well as competitive and other market conditions, call for caution in estimating full-year results based on interim results of operations.
Recent Accounting Pronouncements
The Company's 2024 Form 10-K includes discussion of significant recent accounting pronouncements that either have impacted or may impact our financial statements in the future. There are no updates on significant accounting pronouncements recently adopted or recently issued and not yet adopted that have occurred since the Company filed its 2024 Form 10-K.
v3.25.1
Accounts Receivable, Net
 3 Months Ended
Mar. 31, 2025
Receivables [Abstract]  
Accounts Receivable, Net
Note 3 – Accounts Receivable, Net
The following amounts were included within Accounts receivable, net:
(In millions)March 31, 2025December 31, 2024
Noninsurance customer receivables$13,357 $11,879 
Pharmaceutical manufacturers receivables11,393 10,914 
Insurance customer receivables1,488 3,199 
Other receivables691 162 
Total$26,154 
Accounts receivable, net classified as assets of businesses held for sale
(1,927)
Total$26,929 $24,227 
These accounts receivable are reported net of our allowances of $5.7 billion and $5.0 billion as of March 31, 2025 and December 31, 2024, respectively. These allowances include contractual allowances for certain rebates receivable with pharmaceutical manufacturers and certain accounts receivable from third-party payors, discounts and claims adjustments issued to customers in the form of client credits, an allowance for current expected credit losses and other non-credit adjustments.
The Company's allowance for current expected credit losses was $296 million as of March 31, 2025 and $84 million as of December 31, 2024.
Accounts Receivable Factoring Facility
The Company maintains an uncommitted factoring facility (the "Facility") under which certain accounts receivable may be sold on a non-recourse basis to a financial institution. The Facility began in July 2023 with an initial term of two years, followed by automatic one-year renewal terms unless terminated by either party. The Facility's total capacity is $1.5 billion.
We sold manufacturer accounts receivable under the Facility of $1.4 billion and $1.9 billion for the three months ended March 31, 2025 and 2024, respectively. For the three months ended March 31, 2025 and 2024, factoring fees paid were not material. As of March 31, 2025 and December 31, 2024, all sold accounts receivable had been collected from pharmaceutical manufacturers. As of March 31, 2025, all collections had been remitted to the financial institution. As of December 31, 2024, there was $1.0 billion of collections from pharmaceutical manufacturers that have not been remitted to the financial institution. Such amounts are recorded within Accrued expenses and other liabilities in the Consolidated Balance Sheets.
v3.25.1
Supplier Finance Program
 3 Months Ended
Mar. 31, 2025
Payables and Accruals [Abstract]  
Supplier Finance Program
Note 4 – Supplier Finance Program
The Company facilitates a voluntary supplier finance program (the "Program") that provides suppliers the opportunity to sell their accounts receivable due from us (i.e., our payment obligations to the suppliers) to a financial institution, on a non-recourse basis, in order to be paid earlier than our payment terms require.
As of each of March 31, 2025 and December 31, 2024, $1.6 billion of the Company's outstanding payment obligations were confirmed as valid within the Program by the financial institution and are reflected in Accounts payable in the Consolidated Balance Sheets. The amounts confirmed as valid for both periods are predominately associated with one supplier.
As of March 31, 2025, we have been informed by the financial institution that $563 million of the Company's outstanding payment obligations were voluntarily elected by suppliers to be sold to the financial institution under the Program.
v3.25.1
Divestiture
 3 Months Ended
Mar. 31, 2025
Discontinued Operations and Disposal Groups [Abstract]  
Divestiture
Note 5 – Divestiture
On March 19, 2025, the Company completed the sale of our Medicare Advantage, Medicare Individual Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits, and CareAllies® businesses (the "Disposal Group" or the "HCSC transaction"). The purchase price increased from $3.3 billion to $4.8 billion, subject to post-closing contractual adjustments, reflecting higher statutory surplus for the legal entities when conveyed to HCSC.
For the three months ended March 31, 2025, the Company recognized a gain of $37 million pre-tax ($112 million after-tax) within Gain (loss) on sale of businesses in the Consolidated Statements of Income. The Company received $4.2 billion cash proceeds at closing. We expect receipt of the remaining $0.6 billion in the fourth quarter of 2025 upon HCSC's collection of amounts due from the Centers for Medicare and Medicaid Services.
The Company determined that the Disposal Group met the criteria to be classified as held for sale and aggregated and classified the assets and liabilities as held for sale in our Consolidated Balance Sheets as of December 31, 2024. The assets and liabilities held for sale as of December 31, 2024 were as follows:

(In millions)December 31, 2024
Cash and cash equivalents$1,339 
Investments1,444 
Accounts receivable, net1,927 
Other assets, including Goodwill (1)
2,294 
Total assets of businesses held for sale7,004 
Insurance and contractholder liabilities1,579 
All other liabilities831 
Total liabilities of businesses held for sale$2,410 
(1) Includes Goodwill of $94 million as of December 31, 2024.
Integration and Transaction-Related Costs
In 2025 and 2024, the Company incurred transaction-related costs associated with the HCSC transaction. These costs incurred consisted primarily of certain projects to separate the Company's systems, products and services; fees for legal, advisory and other professional services; and certain employment-related costs. These costs were $216 million pre-tax ($164 million after-tax) for the three months ended March 31, 2025, compared with $37 million pre-tax ($29 million after-tax) for the three months ended March 31, 2024.
v3.25.1
Earnings Per Share
 3 Months Ended
Mar. 31, 2025
Earnings Per Share [Abstract]  
Earnings Per Share
Note 6 – Earnings Per Share
Basic and diluted earnings per share were computed as follows:
Three Months Ended
March 31, 2025March 31, 2024
(Shares in thousands, dollars in millions, except per share amounts)BasicEffect of
Dilution		DilutedBasicEffect of
Dilution		Diluted
Shareholders' net income (loss)
$1,323 $1,323 $(277)$(277)
Shares:
Weighted average270,867 270,867 286,465 286,465 
Common stock equivalents2,086 2,086 — — 
Total shares270,867 2,086 272,953 286,465 — 286,465 
Earnings per share$4.88 $(0.03)$4.85 $(0.97)$— $(0.97)
For the three months ended March 31, 2025, 2.3 million outstanding employee stock options were excluded in the computation of diluted earnings per share because their effect was anti-dilutive. For the three months ended March 31, 2024, due to the Shareholders' net loss, 8.2 million outstanding employee stock options, unvested restricted stock grants and units, and strategic performance shares were excluded in the computation of diluted earnings per share because their effect was anti-dilutive.
The Company held approximately 134.1 million shares of common stock in treasury as of March 31, 2025, 128.7 million shares as of December 31, 2024 and 117.8 million shares as of March 31, 2024.
v3.25.1
Debt
 3 Months Ended
Mar. 31, 2025
Debt Disclosure [Abstract]  
Debt
Note 7 – Debt
Short-Term and Long-Term Debt. During the three months ended March 31, 2025, the Company redeemed at par its $700 million 5.685% senior notes that were due March 2026. For more information regarding our short-term and long-term debt, see Note 7 of the Company's 2024 Form 10-K.
Revolving Credit Agreements. Our revolving credit agreements provide us with the ability to borrow amounts for general corporate purposes, including providing liquidity support if necessary under our commercial paper program discussed below. As of March 31, 2025, there were no outstanding balances under these revolving credit agreements.

In April 2025, the Company replaced its previous revolving credit agreements and entered into a $6.5 billion, five-year revolving credit and letter of credit agreement that will mature in April 2030, with an option to extend the maturity date for additional one-year periods, subject to consent of the banks (the "Credit Agreement"). The Company can borrow up to $6.5 billion under the Credit Agreement for general corporate purposes, with up to $500 million available for issuance of letters of credit.

The Credit Agreement includes an option to increase commitments up to $1.5 billion for a maximum total commitment of $8.0 billion. The Credit Agreement allows for borrowings at either a base rate, term Secured Overnight Financing Rate ("SOFR") or daily simple SOFR plus, in each case, an applicable margin based on the Company's senior unsecured credit ratings.

The Credit Agreement also contains customary covenants and restrictions, including a financial covenant that the Company's leverage ratio, as defined in the Credit Agreement, may not exceed 60%, subject to certain exceptions upon the consummation of an acquisition.
Commercial Paper. Under our commercial paper program, we may issue short-term, unsecured commercial paper notes privately placed on a discounted basis through certain broker-dealers at any time not to exceed an aggregate amount of $6.5 billion. Amounts available under the program may be borrowed, repaid and re-borrowed from time to time. The net proceeds of issuances have been and are expected to be used for general corporate purposes. There was no commercial paper outstanding balance as of March 31, 2025.
Debt Covenants. The Company was in compliance with its debt covenants as of March 31, 2025.
Interest Expense. Interest expense on long-term and short-term debt was $362 million for the three months ended March 31, 2025 and $369 million for the three months ended March 31, 2024.
v3.25.1
Common and Preferred Stock
 3 Months Ended
Mar. 31, 2025
Equity [Abstract]  
Common and Preferred Stock
Note 8 – Common and Preferred Stock
Dividends

The following table provides details of the Company's dividend payments:
Record DatePayment DateAmount per Share
Total Amount Paid (in millions)
2025
March 5, 2025March 20, 2025$1.51$412
2024
March 6, 2024March 21, 2024$1.40$401
On April 23, 2025, the Board of Directors declared the second quarter cash dividend of $1.51 per share of The Cigna Group common stock to be paid on June 18, 2025 to shareholders of record on June 3, 2025. The Company currently intends to pay regular quarterly dividends, with future declarations subject to approval by its Board of Directors and the Board of Director's determination that the declaration of dividends remains in the best interests of The Cigna Group and its shareholders. The decision of whether to pay future dividends and the amount of any such dividends will be based on the Company's financial position, results of operations, cash flows, capital requirements, the requirements of applicable law and any other factors the Board may deem relevant.
v3.25.1
Insurance and Contractholder Liabilities
 3 Months Ended
Mar. 31, 2025
Insurance Loss Reserves [Abstract]  
Insurance and Contractholder Liabilities Insurance and Contractholder Liabilities
A.Account Balances – Insurance and Contractholder Liabilities
The Company's insurance and contractholder liabilities were comprised of the following:
March 31, 2025December 31, 2024March 31, 2024
(In millions)CurrentNon-currentTotalCurrentNon-currentTotalTotal
Unpaid claims and claim expenses
Cigna Healthcare
$4,452 $56 $4,508 $4,932 $86 $5,018 $5,863 
Other172 194 366 147 144 291 260 
Future policy benefits
Cigna Healthcare
38 154 192 91 507 598 607 
Other Operations151 3,157 3,308 157 3,140 3,297 3,460 
Contractholder deposit funds
Cigna Healthcare
— — — 9 115 124 141 
Other Operations348 5,903 6,251 366 5,958 6,324 6,452 
Market risk benefits30 800 830 25 760 785 891 
Unearned premiums793 45 838 753 31 784 836 
Total6,480 10,741 17,221 18,510
Insurance and contractholder liabilities classified as liabilities of businesses held for sale (1)
(1,092)(487)(1,579)(2,081)
Total insurance and contractholder liabilities$5,984 $10,309 $16,293 $5,388 $10,254 $15,642 $16,429 
(1) Amounts classified as liabilities of businesses held for sale include $983 million of Unpaid claims, $408 million of Future policy benefits, $85 million of Unearned premiums and $103 million of Contractholder deposit funds as of December 31, 2024 and $1,378 million of Unpaid claims, $427 million of Future policy benefits, $161 million of Unearned premiums and $115 million of Contractholder deposit funds as of March 31, 2024.

Insurance and contractholder liabilities expected to be paid within one year are classified as current.
Unpaid Claims and Claim Expenses – Cigna Healthcare
This liability reflects estimates of the ultimate cost of claims that have been incurred but not reported, expected development on reported claims, claims that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily comprised of accruals for incentives and other amounts payable to health care professionals and facilities.
The total of incurred but not reported liabilities plus expected development on reported claims and reported claims in process was $4.4 billion at March 31, 2025 and $5.4 billion at March 31, 2024. The decrease was driven by the HCSC transaction.
Activity, net of intercompany transactions, in the unpaid claims liability for the Cigna Healthcare segment was as follows:
Three Months Ended March 31,
(In millions)
2025 (1)
2024 (1)
Beginning balance$5,018 $5,092 
Less: Reinsurance and other amounts recoverable159 236 
Beginning balance, net4,859 4,856 
Incurred costs related to:
Current year10,606 9,452 
Prior years(222)(226)
Total incurred10,384 9,226 
Paid costs related to:
Current year6,078 5,072 
Prior years3,472 3,352 
Total paid9,550 8,424 
Less: Divestiture and other1,323 — 
Ending balance, net4,370 5,658 
Add: Reinsurance and other amounts recoverable138 205 
Ending balance$4,508 $5,863 
(1) Includes unpaid claims amounts classified as liabilities of businesses held for sale prior to the completion of the HCSC transaction. As of December 31, 2024, March 31, 2024 and December 31, 2023, includes $983 million and $1,378 million, $823 million classified as liabilities of businesses held for sale, respectively.
Reinsurance and other amounts recoverable reflect amounts due from reinsurers and policyholders to cover incurred but not reported and pending claims of certain business for which the Company administers the plan benefits without any right of offset. See Note 10 to the Consolidated Financial Statements for additional information on reinsurance.
Variances in incurred costs related to prior years' unpaid claims and claim expenses that resulted from the differences between actual experience and the Company's key assumptions were as follows:
Three Months Ended March 31,
20252024
(Dollars in millions)$
% (1)
$
% (2)
Actual completion factors and other
$96 0.3 %$76 0.2 %
Medical cost trend126 0.3 150 0.4 
Total favorable variance$222 0.6 %$226 0.6 %
(1)Percentage of current year incurred costs as reported for the year ended December 31, 2024.
(2)Percentage of current year incurred costs as reported for the year ended December 31, 2023.

Favorable prior year development in both years primarily reflects lower than expected utilization of medical services as compared to our assumptions.
Future Policy Benefits
Cigna Healthcare

Future policy benefits for the Cigna Healthcare segment were primarily related to the businesses divested to HCSC on March 19, 2025. Excluding the divestiture, changes in the future policy benefits for the three months ended March 31, 2025 and March 31, 2024 were not material.
Other Operations
The weighted average interest rates applied and duration for future policy benefits in Other Operations, consisting of annuity and life insurance products, were as follows:
As of
March 31, 2025March 31, 2024
Interest accretion rate 5.64 %5.64 %
Current discount rate 5.30 %5.16 %
Weighted average duration 10.8 years11.3 years

Obligations for annuities represent discounted periodic benefits to be paid to an individual or groups of individuals over their remaining lives. Other Operations' traditional insurance contracts, which are in run-off, have no premium remaining to be collected; therefore, future policy benefit reserves represent the present value of expected future policy benefits, discounted using the current discount rate, and the remaining amortizable deferred profit liability.
Future policy benefits for Other Operations includes deferred profit liability of $359 million as of March 31, 2025 and $379 million as of March 31, 2024. Future policy benefits excluding deferred profit liability were $3.0 billion as of March 31, 2025, $3.1 billion as of March 31, 2024, $2.9 billion as of December 31, 2024, and $3.2 billion as of December 31, 2023. Undiscounted expected future policy benefits were $4.3 billion as of March 31, 2025 and $4.4 billion as of March 31, 2024. As of March 31, 2025 and March 31, 2024, $0.9 billion and $1.0 billion, respectively, of the future policy benefit reserve was recoverable through treaties with external reinsurers.
Contractholder Deposit Funds
Contractholder deposit fund liabilities within Other Operations were $6.3 billion as of both as of March 31, 2025 and December 31, 2024 and $6.5 billion as of both March 31, 2024 and December 31, 2023. Approximately 38% of the balance is reinsured externally. Activity in these liabilities is presented net of reinsurance in the Consolidated Statements of Cash Flows. Changes in contractholder deposit fund liabilities generally relates to withdrawals and benefit payments, partially offset by deposits and interest credited.
As of March 31, 2025, the weighted average crediting rate, net amount at risk and cash surrender value for contractholder deposit fund liabilities not effectively exited through reinsurance were 3.20%, $2.8 billion and $2.8 billion, respectively. The comparative amounts as of March 31, 2024 were 3.33%, $3.0 billion and $2.8 billion, respectively. More than 99% of the $4.0 billion liability as of both March 31, 2025 and March 31, 2024 not reinsured externally is for contracts with guaranteed interest rates of 3% - 4%, and approximately $1.2 billion as of both March 31, 2025 and March 31, 2024 represented contracts with policies at the guarantee. As of both March 31, 2025 and March 31, 2024, $1.2 billion was 50-150 basis points ("bps") above the guarantee and the remaining $1.6 billion represented contracts above the guarantee that pay the policyholder based on the greater of a guaranteed minimum cash value or the actual cash value. As of both March 31, 2025 and March 31, 2024, more than 90% of these contracts have actual cash values of at least 110% of the guaranteed cash value.
Market Risk Benefits
Liabilities for market risk benefits ("MRBs") consist of variable annuity reinsurance contracts in Other Operations. These liabilities arise under annuities and riders to annuities written by ceding companies that guarantee the benefit received at death and, for a subset of policies, also provide contractholders the option, within 30 days of a policy anniversary after the appropriate waiting period, to elect minimum income payments. The Company's capital market risk exposure on variable annuity reinsurance contracts arises when the reinsured guaranteed minimum benefit exceeds the contractholder's account value in the related underlying mutual funds at the time the insurance benefit is payable under the respective contract. The Company receives and pays premium periodically based on the terms of the reinsurance agreements.
Market risk benefits activity was as follows:
Three Months Ended March 31,
(In millions)20252024
Balance, beginning of year$785 $1,003 
Balance, beginning of year, before the effect of nonperformance risk (own credit risk)838 1,085 
Changes due to expected run-off(4)(3)
Changes due to capital markets versus expected44 (113)
Changes due to policyholder behavior versus expected— (14)
Balance, end of period, before the effect of changes in nonperformance risk (own credit risk)878 955 
Nonperformance risk (own credit risk), end of period(48)(64)
Balance, end of period$830 $891 
Reinsured market risk benefit, end of period$876 $951 
The following table presents the net amount at risk and the average attained age of contractholders (weighted by exposure) for contracts assumed by the Company. The net amount at risk is the amount the Company would have to pay to contractholders if all deaths or annuitizations occurred as of the earliest possible date in accordance with the insurance contract. The Company should be reimbursed in full for these payments unless the Berkshire reinsurance limit is exceeded, as discussed further in Note 10 to the Consolidated Financial Statements.
(Dollars in millions, excludes impact of reinsurance ceded)March 31, 2025March 31, 2024
Net amount at risk$1,412 $1,441 
Average attained age of contractholders (weighted by exposure)77.0 years77.7 years
v3.25.1
Reinsurance
 3 Months Ended
Mar. 31, 2025
Reinsurance Disclosures [Abstract]  
Reinsurance
Note 10 – Reinsurance
The Company's insurance subsidiaries enter into agreements with other insurance companies to limit losses from large exposures and to permit recovery of a portion of incurred losses. Reinsurance is ceded primarily in acquisition and disposition transactions when the underwriting company is not being acquired. Reinsurance does not relieve the originating insurer of liability. Therefore, reinsured liabilities must continue to be reported along with the related reinsurance recoverables. The Company regularly evaluates the financial condition of its reinsurers and monitors concentrations of its credit risk.
The majority of the Company's reinsurance recoverables resulted from acquisition and disposition transactions in which the underwriting company was not acquired. The Company bears the risk of loss if its reinsurers and retrocessionaires do not meet or are unable to meet their reinsurance obligations to the Company. The Company reviews its reinsurance arrangements and establishes reserves against the recoverables primarily for expected credit losses.
The Company's reinsurance recoverables as of March 31, 2025 are presented at amount due by range of external credit rating and collateral level in the following table, with reinsurance recoverables that are market risk benefits separately presented at fair value:
(In millions)
Fair Value of Collateral Contractually Required to Meet or Exceed Carrying Value of Recoverable
Collateral Provisions Exist That May Mitigate Risk of Credit Loss (1)
No CollateralTotal
Ongoing operations
A- equivalent and higher current ratings (2)
$— $6 $177 $183 
BBB- to BBB+ equivalent current credit ratings (2)
— — 63 63 
Not rated101 3 3 107 
Acquisition, disposition or run-off activities
BBB+ equivalent and higher current ratings (2)(3)
304 2,804 208 3,316 
Not rated— 6 1 7 
Total reinsurance recoverables before market risk benefits$405 $2,819 $452 $3,676 
Allowance for uncollectible reinsurance(31)
Market risk benefits876 
Total reinsurance recoverables (4)
$4,521 
(1)Includes collateral provisions requiring the reinsurer to fully collateralize its obligation if its external credit rating is downgraded to a specified level.
(2)Certified by a nationally recognized statistical ratings organization ("NRSRO").
(3)Comprised of six reinsurers of which 75% is held by two reinsurers, Lincoln National Life Insurance Company and Lincoln Life and Annuity Company of New York.
(4)Includes $146 million of current reinsurance recoverables that are reported in Other current assets.
The Company entered into an agreement with Berkshire to effectively exit the variable annuity reinsurance business via a reinsurance transaction in 2013. Variable annuity contracts are accounted for as assumed and ceded reinsurance and categorized as market risk benefits as discussed in Note 9 to the Consolidated Financial Statements. Berkshire reinsured 100% of the Company's future cash flows in this business, net of other reinsurance arrangements existing at that time. The reinsurance agreement is subject to an overall limit, with approximately $3.0 billion remaining at March 31, 2025. As a result of the reinsurance transaction, amounts payable are offset by a corresponding reinsurance recoverable, provided the increased recoverable remains within the overall Berkshire limit. As of both March 31, 2025 and 2024, market risk benefits (shown in the table net of nonperformance risk as of March 31, 2025) were predominantly reinsured by Berkshire, which is rated AA+ by an NRSRO. As of March 31, 2025, approximately 90% of the Berkshire recoverable is secured by assets in a trust.
v3.25.1
Investments
 3 Months Ended
Mar. 31, 2025
Investments [Abstract]  
Investments
Note 11 – Investments
The following table summarizes the Company's investments by category and current or long-term classification:
March 31, 2025December 31, 2024
(In millions)CurrentLong-TermTotalCurrentLong-TermTotal
Debt securities$454 $7,761 $8,215 $463 $8,960 $9,423 
Equity securities11 548 559 7 554 561 
Commercial mortgage loans66 1,228 1,294 108 1,243 1,351 
Policy loans— 1,128 1,128 — 1,156 1,156 
Other long-term investments— 4,685 4,685 — 4,576 4,576 
Short-term investments196 — 196 170 — 170 
Total$748 $16,489 $17,237 
Investments classified as assets of businesses held for sale (1)
(83)(1,361)(1,444)
Investments per Consolidated Balance Sheets$727 $15,350 $16,077 $665 $15,128 $15,793 
(1) Investments related to the HCSC transaction that were held for sale as of December 31, 2024. These investments were primarily comprised of debt securities.
Investment Portfolio
Debt Securities
The amortized cost and fair value by contractual maturity periods for debt securities were as follows as of March 31, 2025:
(In millions)Amortized
Cost		Fair
Value
Due in one year or less$622 $555 
Due after one year through five years3,334 3,224 
Due after five years through ten years2,388 2,270 
Due after ten years2,036 1,837 
Mortgage and other asset-backed securities357 329 
Total$8,737 $8,215 
Actual maturities of these securities could differ from their contractual maturities used in the table above because issuers may have the right to call or prepay obligations, with or without penalties.
Gross unrealized appreciation (depreciation) on debt securities by type of issuer is shown below:
(In millions)Amortized
Cost		Allowance for Credit LossUnrealized
Appreciation		Unrealized
Depreciation		Fair
Value
March 31, 2025
Federal government and agency$211 $— $16 $(4)$223 
State and local government24 — 1 — 25 
Foreign government359 — 8 (9)358 
Corporate7,786 (107)116 (515)7,280 
Mortgage and other asset-backed357 — 2 (30)329 
Total$8,737 $(107)$143 $(558)$8,215 
December 31, 2024
Federal government and agency$276 $— $14 $(9)$281 
State and local government37 — 1 (1)37 
Foreign government350 — 5 (11)344 
Corporate9,091 (111)102 (659)8,423 
Mortgage and other asset-backed371 — 1 (34)338 
Total$10,125 $(111)$123 $(714)$9,423 
Review of Declines in Fair Value. Management reviews debt securities in an unrealized loss position to determine whether a credit loss allowance is needed based on criteria that include severity of decline; financial health and specific prospects of the issuer; and changes in the regulatory, economic or general market environment of the issuer's industry or geographic region.
The table below summarizes debt securities with a decline in fair value from amortized cost for which an allowance for credit losses has not been recorded (by investment grade and the length of time these securities have been in an unrealized loss position). Unrealized depreciation on these debt securities is primarily due to declines in fair value resulting from increasing interest rates since these securities were purchased.
March 31, 2025December 31, 2024
(Dollars in millions)Fair
Value		Amortized
Cost		Unrealized
Depreciation		Number
of Issues		Fair
Value		Amortized
Cost		Unrealized
Depreciation		Number
of Issues
One year or less
Investment grade$567 $573 $(6)353$1,203 $1,227 $(24)545 
Below investment grade220 228 (8)802245 250 (5)739 
More than one year
Investment grade3,818 4,319 (501)1,0804,687 5,319 (632)1,297 
Below investment grade325 368 (43)107416 469 (53)123 
Total$4,930 $5,488 $(558)2,342 $6,551 $7,265 $(714)2,704 
Equity Securities
The following table provides the values of the Company's equity security investments:
March 31, 2025 December 31, 2024
(In millions) CostCarrying Value CostCarrying Value
Equity securities with readily determinable fair values$637 $38 $635 $37 
Equity securities with no readily determinable fair value3,217 521 3,215 524 
Total$3,854 $559 $3,850 $561 
Commercial Mortgage Loans
Mortgage loans held by the Company are made exclusively to commercial borrowers and are diversified by property type, location and borrower. Loans are generally issued at fixed rates of interest and are secured by high-quality, primarily completed and substantially leased operating properties.
The Company regularly evaluates and monitors credit risk from the initial mortgage loan underwriting and throughout the investment holding period. The annual portfolio review performed in the second quarter of 2024 confirmed ongoing strong overall credit quality in line with the previous year's results. For more information on the Company's accounting policies and methodologies regarding these investments, see Note 11 in the Company's 2024 Form 10-K.
The following table summarizes the credit risk profile of the Company's commercial mortgage loan portfolio:

(Dollars in millions)March 31, 2025December 31, 2024
Loan-to-Value RatioCarrying ValueAverage Debt Service Coverage RatioAverage Loan-to-Value RatioCarrying ValueAverage Debt Service Coverage RatioAverage Loan-to-Value Ratio
Below 60%$503 2.05$547 2.07
60% to 79%628 1.71595 1.83
80% to 100%163 0.88209 0.51
Total$1,294 1.7269 %$1,351 1.7069 %
Other Long-Term Investments
Other long-term investments include investments in unconsolidated entities, including certain limited partnerships and limited liability companies holding real estate, securities or loans. These investments are carried at cost plus the Company's ownership percentage of reporting income or loss, based on the financial statements of the underlying investments that are generally reported at fair value. Income or loss from these investments is reported on a one quarter lag due to the timing of when financial information is received from the general partner or manager of the investments.
Other long-term investments also include investment real estate carried at depreciated cost less any impairment write-downs to fair value when cash flow estimates indicate that the carrying value may not be recoverable. Additionally, statutory and other restricted deposits and foreign currency swaps carried at fair value are reported in the table below as Other. The following table provides the carrying value information for these investments:
Carrying Value as of
(In millions)March 31, 2025December 31, 2024
Real estate investments$1,808 $1,763 
Securities partnerships2,660 2,587 
Other217 226 
Total$4,685 $4,576 
Derivative Financial Instruments
The Company uses derivative financial instruments to manage the characteristics of investment assets (such as duration, yield, currency and liquidity) to meet the varying demands of the related insurance and contractholder liabilities. The Company also uses derivative financial instruments to hedge the risk of changes in the net assets of certain of its foreign subsidiaries due to changes in foreign currency exchange rates and to hedge the interest rate risk of certain long-term debt.
As of March 31, 2025, the notional value of interest rate swap contracts increased to $3.0 billion compared to $2.7 billion as of December 31, 2024. There were no other material changes to the Company's derivative financial instruments during the three months ended March 31, 2025. Please refer to the Company's 2024 Form 10-K for further discussion of the types of derivative financial instruments and associated accounting policies. The effects of derivative financial instruments used in our individual hedging strategies were not material to the Consolidated Financial Statements as of March 31, 2025 and December 31, 2024. The gross fair values of our derivative financial instruments are presented in Note 12 to the Consolidated Financial Statements.
Investment Gains and LossesNet investment losses before income taxes were $2 million for the three months ended March 31, 2025 versus $1,836 million for the three months ended March 31, 2024. This decrease was primarily driven by the impairment of equity securities in 2024. These amounts exclude investment gains and losses attributed to the Company's separate accounts because those gains and losses generally accrue directly to separate account policyholders.
v3.25.1
Fair Value Measurements
 3 Months Ended
Mar. 31, 2025
Fair Value Disclosures [Abstract]  
Fair Value Measurements
Note 12 – Fair Value Measurements
For a description of the policies, methods and assumptions that are used to estimate fair value and determine the fair value hierarchy for each class of financial instruments, see Note 12 in the Company's 2024 Form 10-K.
Financial Assets and Financial Liabilities Carried at Fair Value
The following table provides information about the Company's financial assets and liabilities carried at fair value. Further information regarding insurance assets and liabilities carried at fair value is provided in Note 9E to the Consolidated Financial Statements. Separate account assets are also recorded at fair value on the Company's Consolidated Balance Sheets and are reported separately in the Separate Accounts section below as gains and losses related to these assets generally accrue directly to contractholders.
(In millions)Quoted Prices in Active Markets for Identical Assets
(Level 1)		Significant Other Observable Inputs
(Level 2)		Significant Unobservable Inputs
(Level 3)		Total
March 31,
2025		December 31, 2024March 31,
2025		December 31, 2024March 31,
2025		December 31, 2024March 31,
2025		December 31, 2024
Financial assets at fair value
Debt securities
Federal government and agency$104 $165 $119 $116 $— $— $223 $281 
State and local government— — 25 37 — — 25 37 
Foreign government— — 358 344 — — 358 344 
Corporate
— — 6,951 8,049 329 374 7,280 8,423 
Mortgage and other asset-backed— — 285 295 44 43 329 338 
Total debt securities104 165 7,738 8,841 373 417 8,215 9,423 
Equity securities (1)
1 1 37 36 — — 38 37 
Short-term investments— — 196 170 — — 196 170 
Derivative assets— — 153 168 — — 153 168 
Financial liabilities at fair value
Derivative liabilities$— $— $2 $1 $— $— $2 $1 
(1)Excludes certain equity securities that have no readily determinable fair value.
Level 3 Financial Assets and Financial Liabilities
Certain inputs for instruments classified in Level 3 are unobservable (supported by little or no market activity) and significant to their resulting fair value measurement. Unobservable inputs reflect the Company's best estimate of what hypothetical market participants would use to determine a transaction price for the asset or liability at the reporting date. Additionally, as discussed in Note 9E in the Company's 2024 Form 10-K, the Company classifies variable annuity assets and liabilities in Level 3 of the fair value hierarchy.
Quantitative Information about Unobservable Inputs
The significant unobservable input used to value our corporate and government debt securities and mortgage and other asset-backed securities is an adjustment for liquidity. This adjustment is needed to reflect current market conditions and issuer circumstances when there is limited trading activity for the security.

The following table summarizes the fair value and significant unobservable inputs that were developed directly by the Company and used in pricing these debt securities. The range and weighted average basis point amounts for liquidity reflect the Company's best estimates of the unobservable adjustments a market participant would make to calculate these fair values. An increase in liquidity spread adjustments would result in a lower fair value measurement, while a decrease would result in a higher fair value measurement.

Fair Value as ofUnobservable Adjustment Range (Weighted Average by Quantity) as of
(Fair value in millions)March 31,
2025		December 31,
2024
Unobservable Input
March 31, 2025
March 31,
2025		December 31,
2024
Debt securities
Corporate$329 $373 Liquidity
5 - 1475 (300)
bps
60 - 1520 (370)
bps
Mortgage and other asset-backed securities44 43 Liquidity
105 - 575 (290)
bps
100 - 550 (280)
bps
Other debt securities— 1 
Total Level 3 debt securities$373 $417 
Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value
The following table summarizes the changes in financial assets and financial liabilities classified in Level 3. Gains and losses reported in the table may include net changes in fair value that are attributable to both observable and unobservable inputs.
Three Months Ended
March 31,
(In millions)20252024
Debt securities
Beginning balance$417 $447 
Losses included in Shareholders' net income (loss)
(10)(21)
Gains (losses) included in Other comprehensive loss
7 (3)
Purchases, sales and settlements
Purchases2 — 
Settlements(31)(14)
Total purchases, sales and settlements(29)(14)
Transfers into / (out of) Level 3
Transfers into Level 318 16 
Transfers out of Level 3(30)(3)
Total transfers into / (out of) Level 3(12)13 
Ending balance$373 $422 
Total losses included in Shareholders' net income (loss) attributable to instruments held at the reporting date
$(13)$(21)
Change in unrealized gain or (loss) included in Other comprehensive loss for assets held at the end of the reporting period
$3 $(4)

Total gains and losses included in Shareholders' net income (loss) in the tables above are reflected in the Consolidated Statements of Income as Net investment losses and Net investment income. Gains and losses included in Other comprehensive loss, net of tax in the tables above are reflected in Net unrealized (depreciation) appreciation on securities and derivatives in the Consolidated Statements of Comprehensive Income.
Transfers into or out of the Level 3 category occur when unobservable inputs, such as the Company's best estimate of what a market participant would use to determine a current transaction price, become more or less significant to the fair value measurement. Market activity typically decreases during periods of economic uncertainty, and this decrease in activity reduces the availability of market observable data. As a result, the level of unobservable judgment that must be applied to the pricing of certain instruments increases and is typically observed through the widening of liquidity spreads. Transfers between Level 2 and Level 3 during 2025 and 2024 primarily reflected changes in liquidity estimates for certain private placement issuers across several sectors. See discussion under Quantitative Information about Unobservable Inputs above for more information.
Separate Accounts
The investment income and fair value gains and losses of Separate account assets generally accrue directly to the contractholders and, together with their deposits and withdrawals, are excluded from the Company's Consolidated Statements of Income and Cash Flows. The separate account activity for the three months ended March 31, 2025 and 2024 was primarily driven by changes in the market values of the underlying separate account investments.
Fair values of Separate account assets were as follows:
Quoted Prices in Active Markets for Identical Assets
(Level 1)		Significant Other Observable Inputs
(Level 2)		Significant Unobservable Inputs
(Level 3)		Total
(In millions)March 31,
2025		December 31,
2024		March 31,
2025		December 31,
2024		March 31,
2025		December 31,
2024		March 31,
2025		December 31,
2024
Guaranteed separate accounts (See Note 16)
$227 $231 $328 $345 $— $— $555 $576 
Non-guaranteed separate accounts (1)
275 267 5,559 5,575 255 228 6,089 6,070 
Subtotal$502 $498 $5,887 $5,920 $255 $228 6,644 6,646 
Non-guaranteed separate accounts priced at net asset value as a practical expedient (1)
633 632 
Total$7,277 $7,278 
Non-guaranteed separate accounts include $3.8 billion as of each of March 31, 2025 and December 31, 2024 in assets supporting the Company's pension plans, including $0.2 billion classified in Level 3 as of each of March 31, 2025 and December 31, 2024, respectively. Non-guaranteed separate accounts are primarily comprised of securities partnerships, real estate and real estate funds.
Separate account assets classified in Level 3 primarily support the Company's pension plans and include certain newly issued, privately placed, complex or illiquid securities that are priced using methods discussed above, as well as commercial mortgage loans. Activity, including transfers into and out of Level 3, was not material for the three months ended March 31, 2025 or 2024.
Assets and Liabilities Measured at Fair Value under Certain Conditions
Some financial assets and liabilities are not carried at fair value, such as commercial mortgage loans that are carried at unpaid principal, investment real estate that is carried at depreciated cost and equity securities with no readily determinable fair value when there are no observable market transactions. However, these financial assets and liabilities may be measured using fair value under certain conditions, such as when investments become impaired and are written down to their fair value, or when there are observable price changes from orderly market transactions of equity securities that otherwise had no readily determinable fair value.

For the three months ended March 31, 2025, impairments recognized requiring the assets and liabilities described above to be measured at fair value were not material. In the first quarter of 2024, we determined our investment in VillageMD was impaired and recorded a $1.8 billion loss in Net investment losses in the Company's Consolidated Statements of Income. Observable price changes for equity securities with no readily determinable fair value were not material for the three months ended March 31, 2025 and March 31, 2024.
Fair Value Disclosures for Financial Instruments Not Carried at Fair Value
The following table includes the Company's financial instruments not recorded at fair value but for which fair value disclosure is required. In addition to universal life products and finance leases, financial instruments that are carried in the Company's Consolidated Balance Sheets at amounts that approximate fair value are excluded from the following table.
Classification in Fair Value HierarchyMarch 31, 2025December 31, 2024
(In millions)Fair ValueCarrying ValueFair ValueCarrying Value
Commercial mortgage loansLevel 3$1,228 $1,294 $1,256 $1,351 
Long-term debt, including current maturities, excluding finance leasesLevel 2$28,149 $30,371 $28,392 $31,008 
v3.25.1
Accumulated Other Comprehensive Income (Loss)
 3 Months Ended
Mar. 31, 2025
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]  
Accumulated Other Comprehensive Income (Loss)
Note 13 – Accumulated Other Comprehensive Income (Loss)
Accumulated Other Comprehensive Income (Loss) ("AOCI") includes net unrealized (depreciation) appreciation on securities and derivatives, change in discount rate and instrument-specific credit risk for certain long-duration insurance contractholder liabilities (see Note 9 to the Consolidated Financial Statements), foreign currency translation, and the net postretirement benefits liability adjustment. AOCI includes the Company's share from unconsolidated entities reported on the equity method. Generally, tax effects in AOCI are established at the currently enacted tax rate and reclassified to Shareholders' net income (loss) in the same period that the related pre-tax AOCI reclassifications are recognized.

Shareholders' other comprehensive loss, net of tax, for the three months ended March 31, 2025 and March 31, 2024 is primarily attributable to the change in discount rates for certain long-duration liabilities and unrealized changes in the market values of securities and derivatives, including the impacts from unconsolidated entities reported on the equity method.

Changes in the components of AOCI were as follows:
Three Months Ended
March 31,
(In millions)20252024
Securities and Derivatives
Beginning balance$832 $171 
Unrealized (depreciation) appreciation on securities and derivatives, before reclassification, net of tax benefit (expense) of $49 and $(39), respectively
(134)104 
Amounts reclassified to Shareholders' net income (loss), net of tax (benefit) of $(9) and $(5), respectively
34 17 
Other comprehensive (loss) income, net of tax
(100)121 
Ending balance$732 $292 
Net long-duration insurance and contractholder liabilities measurement adjustments
Beginning balance$(2,038)$(971)
Net current period change in discount rate for certain long-duration liabilities, before reclassification, net of tax benefit of $33 and $186, respectively
(108)(546)
Amounts reclassified to Shareholders' net income (loss), net of tax expense of $16 and $—, respectively
(56)— 
Net current period change in discount rate for certain long-duration liabilities, net of tax benefit of $49 and $186, respectively
(164)(546)
Net current period change in instrument-specific credit risk for market risk benefits, net of tax benefit of $1 and $4, respectively
(4)(14)
Other comprehensive (loss), net of tax
(168)(560)
Ending balance$(2,206)$(1,531)
Translation of foreign currencies
Beginning balance$(198)$(149)
Net translation of foreign currencies, before reclassification, net of tax (expense) of $(6) and $(2), respectively
13 (26)
Ending balance$(185)$(175)
Postretirement benefits liability
Beginning balance$(937)$(915)
Amounts reclassified to Shareholders' net income, net of tax (benefit) of $(2) and $(3), respectively
6 5 
Ending balance$(931)$(910)
Total Accumulated other comprehensive loss
Beginning balance$(2,341)$(1,864)
Shareholders' other comprehensive (loss), net of tax benefit of $82 and $141, respectively
(249)(460)
Ending balance$(2,590)$(2,324)
v3.25.1
Strategic Optimization Program
 3 Months Ended
Mar. 31, 2025
Restructuring and Related Activities [Abstract]  
Strategic Optimization Program
Note 14 – Strategic Optimization Program
In 2025, the Company commenced an enterprise-wide initiative to evolve our business and deliver a more efficient and improved experience for our patients, providers and customers. This program is expected to continue through December 2026 and include severance and other employee costs, accelerated asset amortization, and the operating results of certain small non-strategic businesses that we plan to discontinue. As we continue to evaluate additional opportunities to improve the overall efficiency and effectiveness of our operations, we anticipate future charges.

During the three months ended March 31, 2025, we reported total costs of $215 million, pre-tax ($163 million, after-tax) associated with this initiative, including a charge in Selling, general and administrative expenses of $198 million, pre-tax ($150 million, after-tax) that was primarily associated with employee severance. The remainder reflects the operating results of certain non-strategic businesses. We expect substantially all of the accrued liability to be paid by the end of 2025.

The following table summarizes a roll forward of the accrued liability recorded in Accrued expenses and other liabilities during the three months ended March 31, 2025:
(In millions)
Balance, December 31, 2024
$— 
First quarter 2025 charge
171 
2025 payments
(10)
Balance, March 31, 2025
$161 
v3.25.1
Income Taxes
 3 Months Ended
Mar. 31, 2025
Income Tax Disclosure [Abstract]  
Income Taxes
Note 15 – Income Taxes
Income Tax Expense
The 14.5% effective tax rate for the three months ended March 31, 2025 was lower than the 368.4% rate for the three months ended March 31, 2024 primarily due to the absence of a valuation allowance related to the impairment of equity securities in 2024, partially offset by the absence of tax benefits recorded in 2024 related to the release of tax reserves following favorable state audit resolutions and the impact related to the HCSC transaction.
As of March 31, 2025, we had approximately $856 million in deferred tax assets ("DTAs") associated with the impairment of equity securities as well as unrealized investment losses. A valuation allowance of $636 million, of which $427 million was established in the three months ended March 31, 2024, drove the higher effective tax rate and was almost entirely related to the impairment of equity securities discussed in Note 11 to the Consolidated Financial Statements. We have determined that a valuation allowance against the remaining DTAs is not currently required based on the Company's loss carryback capacity and ability and intent to hold certain securities until recovery. We continue to monitor and evaluate the need for any additional valuation allowance.
v3.25.1
Contingencies and Other Matters
 3 Months Ended
Mar. 31, 2025
Commitments and Contingencies Disclosure [Abstract]  
Contingencies and Other Matters
Note 16 – Contingencies and Other Matters
The Company, through its subsidiaries, is contingently liable for various guarantees provided in the ordinary course of business.
A.Financial Guarantees: Retiree and Life Insurance Benefits
The Company guarantees that separate account assets will be sufficient to pay certain life insurance or retiree benefits. For the majority of these benefits, the sponsoring employers are primarily responsible for ensuring that assets are sufficient to pay these benefits and are required to maintain assets that exceed a certain percentage of benefit obligations. If employers fail to do so, the Company or an affiliate of the buyer of the retirement benefits business has the right to redirect the management of the related assets to provide for benefit payments. As of March 31, 2025, employers maintained assets that generally exceeded the benefit obligations under these arrangements of approximately $410 million. An additional liability is established if management believes that the Company will be required to make payments under the guarantees; there were no additional liabilities required for these guarantees, net of reinsurance, as of March 31, 2025. Separate account assets supporting these guarantees are classified in Levels 1 and 2 of the GAAP fair value hierarchy.
The Company does not expect that these financial guarantees will have a material effect on the Company's consolidated results of operations, liquidity or financial condition.
B.Certain Other Guarantees
The Company had indemnification obligations as of March 31, 2025 in connection with acquisition and disposition transactions. These indemnification obligations are triggered by the breach of representations or covenants provided by the Company, such as representations for the presentation of financial statements, filing of tax returns, compliance with laws or regulations, or identification of outstanding litigation. These obligations are typically subject to various time limitations, defined by the contract or by operation of law, such as statutes of limitation. In some cases, the maximum potential amount due is subject to contractual limitations based on a stated dollar amount or a percentage of the transaction purchase price, while in other cases limitations are not specified or applicable. The Company does not believe that it is possible to determine the maximum potential amount due under these obligations because not all amounts due under these indemnification obligations are subject to limitation. There were no recorded liabilities for these indemnification obligations as of March 31, 2025.
C.Guaranty Fund Assessments
The Company operates in a regulatory environment that may require its participation in assessments under state insurance guaranty association laws. The Company's exposure to assessments for certain obligations of insolvent insurance companies to policyholders and claimants is based on its share of business written in the relevant jurisdictions. There were no material charges or credits resulting from existing or new guaranty fund assessments for the three months ended March 31, 2025.
Legal and Regulatory Matters
The Company is routinely involved in numerous claims, lawsuits, regulatory inquiries and audits, government investigations, including under the federal False Claims Act and state false claims acts initiated by a government investigating body or by a qui tam relator's filing of a complaint under court seal, and other legal matters arising, for the most part, in the ordinary course of managing a global health services business. Additionally, the Company has received and is cooperating with subpoenas or similar processes from various governmental agencies requesting information, all arising in the normal course of its business. Disputed tax matters arising from audits by the Internal Revenue Service or other state and foreign jurisdictions, including those resulting in litigation, are accounted for under GAAP guidance for uncertain tax positions.
v3.25.1
Segment Information
 3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Segment Information
Note 17 – Segment Information
See Note 1 to the Consolidated Financial Statements for a description of our segments. A description of our basis for reporting segment operating results is outlined below. Intersegment revenues primarily reflect pharmacy and care services transactions between the Evernorth Health Services and Cigna Healthcare segments. The Chairman and Chief Executive Officer is the chief operating decision maker ("CODM") responsible for making decisions about resources to be allocated to the segment and assessing its performance.
The Company uses "pre-tax adjusted income (loss) from operations" and "adjusted revenues" as its principal financial measures of segment operating performance because management, including the CODM, believes these metrics reflect the underlying results of business operations and facilitate analysis of trends in underlying revenue, expenses and profitability to enable resource allocation decisions. We define pre-tax adjusted income (loss) from operations as income (loss) before income taxes excluding pre-tax income (loss) attributable to noncontrolling interests, net investment gains/losses, amortization of acquired intangible assets and special items. The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management, including the CODM, believes are not representative of the underlying results of operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results.
The Company defines adjusted revenues as total revenues excluding the following adjustments: special items and The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Special items are matters that management, including the CODM, believes are not representative of the underlying results of operations due to their nature or size. We exclude these items from this measure because management, including the CODM, believes they are not indicative of past or future underlying performance of the business.
The Company does not report total assets by segment because this is not a metric used by the CODM to allocate resources or evaluate segment performance.
The following table presents the special items charges (benefits) recorded by the Company, as well as the respective financial statement line items impacted:
Three Months Ended March 31,
20252024
(In millions)Pre-taxAfter-taxPre-taxAfter-tax
Integration and transaction-related costs (Selling, general and administrative expenses)$216 $164 $37 $29 
Strategic optimization program (primarily Selling, general and administrative expenses)215 163 — — 
Deferred tax expenses, net (Income taxes, less amount attributable to noncontrolling interests)— 17 — 17 
(Gain) loss on sale of businesses (41)(115)19 (43)
Total impact from special items$390 $229 $56 $3 
Summarized segment financial information was as follows:
(In millions)
Evernorth Health Services
Cigna Healthcare
Other Operations
Corporate and Eliminations
Total
Three months ended March 31, 2025
Revenues from external customers$52,002 $13,168 $94 $— $65,264 
Intersegment revenues1,648 1,231 12 (2,891)
Net investment income
31 133 69 5 238 
Total revenues53,681 14,532 175 (2,886)65,502 
Net investment results from certain equity method investments
— (50)— — (50)
Adjusted revenues$53,681 $14,482 $175 $(2,886)$65,452 
Pharmacy and other service costs51,121 — 
Medical costs— 10,385 
Selling, general and administrative expenses1,024 2,812 
Other segment items (1)
   Interest (expense) and other— 2 
   Less: Income attributable to noncontrolling interests102 — 
Pre-tax adjusted income (loss) from operations1,434 1,287 — (411)2,310 
Income (loss) before income taxes
$1,108 $1,364 $(20)$(804)$1,648 
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) attributable to noncontrolling interests
(102)— — — (102)
Net investment (gains) losses (2)
(4)(47)3 — (48)
Amortization of acquired intangible assets415 7 — — 422 
Special items
Integration and transaction-related costs— — — 216 216 
Strategic optimization program21 — 17 177 215 
(Gain) on sale of businesses(4)(37)— — (41)
Pre-tax adjusted income (loss) from operations$1,434 $1,287 $— $(411)$2,310 
Other segment information
Depreciation and amortization$584 $83 $2 $5 $674 
(1)Other segment items represent the difference between segment adjusted revenues less significant segment expenses and pre-tax adjusted income (loss) from operations, and they do not represent significant segment items relative to the CODM's review and oversight.
(2)Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.
(In millions)
Evernorth Health Services
Cigna Healthcare
Other Operations
Corporate and Eliminations
Total
Three months ended March 31, 2024
Revenues from external customers $44,886 $12,012 $66 $1 $56,965 
Intersegment revenues1,281 1,124 25 (2,430)
Net investment income
59 149 75 7 290 
Total revenues46,226 13,285 166 (2,422)57,255 
Net investment results from certain equity method investments— (8)— — (8)
Adjusted revenues$46,226 $13,277 $166 $(2,422)$57,247 
Pharmacy and other service costs43,838 — 
Medical costs— 9,219 
Selling, general and administrative expenses951 2,720 
Other segment items (1)
Interest (expense) and other— 2 
Less: income attributable to noncontrolling interests77 — 
Pre-tax adjusted income (loss) from operations1,360 1,340 18 (409)2,309 
(Loss) income before income taxes
$(436)$943 $18 $(446)$79 
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) attributable to noncontrolling interests
(77)— — — (77)
Net investment losses (2)
1,456 372 — — 1,828 
Amortization of acquired intangible assets417 6 — — 423 
Special items
Integration and transaction-related costs
— — — 37 37 
Loss on sale of businesses
— 19 — — 19 
Pre-tax adjusted income (loss) from operations$1,360 $1,340 $18 $(409)$2,309 
Other segment information
Depreciation and amortization$606 $124 $1 $10 $741 
(1)Other segment items represent the difference between segment adjusted revenues less significant segment expenses and pre-tax adjusted income (loss) from operations, and they do not represent significant segment items relative to the CODM's review and oversight.
(2)Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.
Revenue from external customers includes Pharmacy revenues, Premiums and Fees and other revenues. The following table presents these revenues by product, premium and service type:
Three Months Ended March 31,
(In millions)20252024
Products (Pharmacy revenues) (ASC 606)
Network revenues$28,212 $24,166 
Home delivery and specialty revenues18,937 16,458 
Other revenues3,077 2,546 
Total Evernorth Health Services
50,226 43,170 
Other Operations
13 17 
Corporate and eliminations(1,606)(1,151)
Total Pharmacy revenues
48,633 42,036 
Insurance premiums (ASC 944)
Cigna Healthcare
U.S. Healthcare
Employer insured4,688 4,393 
Medicare Advantage2,363 2,287 
Stop loss1,868 1,668 
Individual and Family Plans859 1,040 
Other1,872 1,258 
U.S. Healthcare
11,650 10,646 
International Health978 885 
Total Cigna Healthcare12,628 11,531 
Other Operations81 48 
Corporate and eliminations27 24 
Total Premiums
12,736 11,603 
Services (Fees) (ASC 606) and Other revenues (1)
Evernorth Health Services
3,424 2,997 
Cigna Healthcare
1,771 1,605 
Other Operations
12 26 
Corporate and eliminations(1,312)(1,302)
Total Fees and other revenues (1)
3,895 3,326 
Total revenues from external customers$65,264 $56,965 
(1)Other revenues for the three months ended March 31, 2025 and 2024 were $162 million and $90 million, respectively.
Financial and performance guarantees. Evernorth Health Services may also provide certain financial and performance guarantees, including a minimum level of discounts a client may receive, generic utilization rates and various service levels. Clients may be entitled to receive compensation if we fail to meet the guarantees. Actual performance is compared to the contractual guarantee for each measure throughout the period, and the Company defers revenue for any estimated payouts within Accrued expenses and other liabilities (current). These estimates are adjusted and paid following the end of the annual guarantee period. Historically, adjustments to original estimates have not been material. This guarantee liability was $1.9 billion as of both March 31, 2025 and December 31, 2024.
v3.25.1
Insider Trading Arrangements
 3 Months Ended
Mar. 31, 2025
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
v3.25.1
Summary of Significant Accounting Policies (Policies)
 3 Months Ended
Mar. 31, 2025
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The Consolidated Financial Statements include the accounts of The Cigna Group and its consolidated subsidiaries. Intercompany transactions and accounts have been eliminated in consolidation. These Consolidated Financial Statements were prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP"). Certain amounts in the Consolidated Statements of Cash Flows have been reclassified to conform to current year presentation and did not have a significant impact on our Consolidated Financial Statements.

Amounts recorded in the Consolidated Financial Statements necessarily reflect management's estimates and assumptions about medical costs, investment, tax and receivable valuations, interest rates, and other factors. Significant estimates are discussed throughout these Notes; however, actual results could differ from those estimates. The impact of a change in estimate is generally included in earnings in the period of adjustment.
These interim Consolidated Financial Statements are unaudited but include all adjustments (including normal recurring adjustments) necessary, in the opinion of management, for a fair statement of financial position and results of operations for the periods reported.
The interim Consolidated Financial Statements and Notes should be read in conjunction with the Consolidated Financial Statements and Notes included in the 2024 Annual Report on Form 10-K ("2024 Form 10-K"). The Company has not included certain footnote disclosures that would substantially duplicate the disclosures contained in its 2024 Form 10-K, unless the information in those disclosures materially changed or is required by GAAP. The preparation of interim Consolidated Financial Statements necessarily relies heavily on estimates. This and other factors, including the seasonal nature of portions of the health care and related benefits business, as well as competitive and other market conditions, call for caution in estimating full-year results based on interim results of operations.
Recent Accounting Pronouncements, Recently Adopted Accounting Guidance and Accounting Guidance Not Yet Adopted
Recent Accounting Pronouncements
The Company's 2024 Form 10-K includes discussion of significant recent accounting pronouncements that either have impacted or may impact our financial statements in the future. There are no updates on significant accounting pronouncements recently adopted or recently issued and not yet adopted that have occurred since the Company filed its 2024 Form 10-K.
Revenue Recognition Evernorth Health Services may also provide certain financial and performance guarantees, including a minimum level of discounts a client may receive, generic utilization rates and various service levels. Clients may be entitled to receive compensation if we fail to meet the guarantees. Actual performance is compared to the contractual guarantee for each measure throughout the period, and the Company defers revenue for any estimated payouts within Accrued expenses and other liabilities (current). These estimates are adjusted and paid following the end of the annual guarantee period.
v3.25.1
Insurance and Contractholder Liabilities (Policies)
 3 Months Ended
Mar. 31, 2025
Insurance Loss Reserves [Abstract]  
Unpaid Claims and Claims Expenses This liability reflects estimates of the ultimate cost of claims that have been incurred but not reported, expected development on reported claims, claims that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily comprised of accruals for incentives and other amounts payable to health care professionals and facilities.
Future Policy Benefits
Obligations for annuities represent discounted periodic benefits to be paid to an individual or groups of individuals over their remaining lives. Other Operations' traditional insurance contracts, which are in run-off, have no premium remaining to be collected; therefore, future policy benefit reserves represent the present value of expected future policy benefits, discounted using the current discount rate, and the remaining amortizable deferred profit liability.
v3.25.1
Reinsurance (Policies)
 3 Months Ended
Mar. 31, 2025
Reinsurance Disclosures [Abstract]  
Reinsurance
Reinsurance and other amounts recoverable reflect amounts due from reinsurers and policyholders to cover incurred but not reported and pending claims of certain business for which the Company administers the plan benefits without any right of offset. See Note 10 to the Consolidated Financial Statements for additional information on reinsurance.
The Company's insurance subsidiaries enter into agreements with other insurance companies to limit losses from large exposures and to permit recovery of a portion of incurred losses. Reinsurance is ceded primarily in acquisition and disposition transactions when the underwriting company is not being acquired. Reinsurance does not relieve the originating insurer of liability. Therefore, reinsured liabilities must continue to be reported along with the related reinsurance recoverables. The Company regularly evaluates the financial condition of its reinsurers and monitors concentrations of its credit risk.
The Company reviews its reinsurance arrangements and establishes reserves against the recoverables primarily for expected credit losses.Variable annuity contracts are accounted for as assumed and ceded reinsurance and categorized as market risk benefits as discussed in Note 9 to the Consolidated Financial Statements.
v3.25.1
Investments (Policies)
 3 Months Ended
Mar. 31, 2025
Investments [Abstract]  
Investments
Review of Declines in Fair Value. Management reviews debt securities in an unrealized loss position to determine whether a credit loss allowance is needed based on criteria that include severity of decline; financial health and specific prospects of the issuer; and changes in the regulatory, economic or general market environment of the issuer's industry or geographic region.
The Company regularly evaluates and monitors credit risk from the initial mortgage loan underwriting and throughout the investment holding period. The annual portfolio review performed in the second quarter of 2024 confirmed ongoing strong overall credit quality in line with the previous year's results. For more information on the Company's accounting policies and methodologies regarding these investments, see Note 11 in the Company's 2024 Form 10-K.
Other long-term investments include investments in unconsolidated entities, including certain limited partnerships and limited liability companies holding real estate, securities or loans. These investments are carried at cost plus the Company's ownership percentage of reporting income or loss, based on the financial statements of the underlying investments that are generally reported at fair value. Income or loss from these investments is reported on a one quarter lag due to the timing of when financial information is received from the general partner or manager of the investments.
Other long-term investments also include investment real estate carried at depreciated cost less any impairment write-downs to fair value when cash flow estimates indicate that the carrying value may not be recoverable. Additionally, statutory and other restricted deposits and foreign currency swaps carried at fair value are reported in the table below as Other.
Derivative Financial Instruments Please refer to the Company's 2024 Form 10-K for further discussion of the types of derivative financial instruments and associated accounting policies.
v3.25.1
Fair Value Measures and Disclosures (Policies)
 3 Months Ended
Mar. 31, 2025
Fair Value Disclosures [Abstract]  
Fair Value Measurements
For a description of the policies, methods and assumptions that are used to estimate fair value and determine the fair value hierarchy for each class of financial instruments, see Note 12 in the Company's 2024 Form 10-K.
Level 3 Financial Assets and Financial Liabilities
Certain inputs for instruments classified in Level 3 are unobservable (supported by little or no market activity) and significant to their resulting fair value measurement. Unobservable inputs reflect the Company's best estimate of what hypothetical market participants would use to determine a transaction price for the asset or liability at the reporting date. Additionally, as discussed in Note 9E in the Company's 2024 Form 10-K, the Company classifies variable annuity assets and liabilities in Level 3 of the fair value hierarchy.
Quantitative Information about Unobservable Inputs
The significant unobservable input used to value our corporate and government debt securities and mortgage and other asset-backed securities is an adjustment for liquidity. This adjustment is needed to reflect current market conditions and issuer circumstances when there is limited trading activity for the security.
Total gains and losses included in Shareholders' net income (loss) in the tables above are reflected in the Consolidated Statements of Income as Net investment losses and Net investment income. Gains and losses included in Other comprehensive loss, net of tax in the tables above are reflected in Net unrealized (depreciation) appreciation on securities and derivatives in the Consolidated Statements of Comprehensive Income.
Transfers into or out of the Level 3 category occur when unobservable inputs, such as the Company's best estimate of what a market participant would use to determine a current transaction price, become more or less significant to the fair value measurement. Market activity typically decreases during periods of economic uncertainty, and this decrease in activity reduces the availability of market observable data. As a result, the level of unobservable judgment that must be applied to the pricing of certain instruments increases and is typically observed through the widening of liquidity spreads.Assets and Liabilities Measured at Fair Value under Certain Conditions
Some financial assets and liabilities are not carried at fair value, such as commercial mortgage loans that are carried at unpaid principal, investment real estate that is carried at depreciated cost and equity securities with no readily determinable fair value when there are no observable market transactions. However, these financial assets and liabilities may be measured using fair value under certain conditions, such as when investments become impaired and are written down to their fair value, or when there are observable price changes from orderly market transactions of equity securities that otherwise had no readily determinable fair value.
Separate Accounts
Separate Accounts
The investment income and fair value gains and losses of Separate account assets generally accrue directly to the contractholders and, together with their deposits and withdrawals, are excluded from the Company's Consolidated Statements of Income and Cash Flows.Separate account assets classified in Level 3 primarily support the Company's pension plans and include certain newly issued, privately placed, complex or illiquid securities that are priced using methods discussed above, as well as commercial mortgage loans.
v3.25.1
Accumulated Other Comprehensive Income (Loss) (Policies)
 3 Months Ended
Mar. 31, 2025
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]  
AOCI Generally, tax effects in AOCI are established at the currently enacted tax rate and reclassified to Shareholders' net income (loss) in the same period that the related pre-tax AOCI reclassifications are recognized.
v3.25.1
Commitment and Contingencies (Policies)
 3 Months Ended
Mar. 31, 2025
Commitments and Contingencies Disclosure [Abstract]  
Guarantees Financial Guarantees: Retiree and Life Insurance BenefitsThe Company guarantees that separate account assets will be sufficient to pay certain life insurance or retiree benefits. For the majority of these benefits, the sponsoring employers are primarily responsible for ensuring that assets are sufficient to pay these benefits and are required to maintain assets that exceed a certain percentage of benefit obligations. If employers fail to do so, the Company or an affiliate of the buyer of the retirement benefits business has the right to redirect the management of the related assets to provide for benefit payments.An additional liability is established if management believes that the Company will be required to make payments under the guarantees;Separate account assets supporting these guarantees are classified in Levels 1 and 2 of the GAAP fair value hierarchy.Certain Other GuaranteesThe Company had indemnification obligations as of March 31, 2025 in connection with acquisition and disposition transactions. These indemnification obligations are triggered by the breach of representations or covenants provided by the Company, such as representations for the presentation of financial statements, filing of tax returns, compliance with laws or regulations, or identification of outstanding litigation. These obligations are typically subject to various time limitations, defined by the contract or by operation of law, such as statutes of limitation. In some cases, the maximum potential amount due is subject to contractual limitations based on a stated dollar amount or a percentage of the transaction purchase price, while in other cases limitations are not specified or applicable. The Company does not believe that it is possible to determine the maximum potential amount due under these obligations because not all amounts due under these indemnification obligations are subject to limitation.
v3.25.1
Segment Reporting (Policies)
 3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Segment Information Intersegment revenues primarily reflect pharmacy and care services transactions between the Evernorth Health Services and Cigna Healthcare segments. The Chairman and Chief Executive Officer is the chief operating decision maker ("CODM") responsible for making decisions about resources to be allocated to the segment and assessing its performance.
The Company uses "pre-tax adjusted income (loss) from operations" and "adjusted revenues" as its principal financial measures of segment operating performance because management, including the CODM, believes these metrics reflect the underlying results of business operations and facilitate analysis of trends in underlying revenue, expenses and profitability to enable resource allocation decisions. We define pre-tax adjusted income (loss) from operations as income (loss) before income taxes excluding pre-tax income (loss) attributable to noncontrolling interests, net investment gains/losses, amortization of acquired intangible assets and special items. The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management, including the CODM, believes are not representative of the underlying results of operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results.
The Company defines adjusted revenues as total revenues excluding the following adjustments: special items and The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Special items are matters that management, including the CODM, believes are not representative of the underlying results of operations due to their nature or size. We exclude these items from this measure because management, including the CODM, believes they are not indicative of past or future underlying performance of the business.
v3.25.1
Accounts Receivable, Net (Tables)
 3 Months Ended
Mar. 31, 2025
Receivables [Abstract]  
Accounts Receivable, Net
The following amounts were included within Accounts receivable, net:
(In millions)March 31, 2025December 31, 2024
Noninsurance customer receivables$13,357 $11,879 
Pharmaceutical manufacturers receivables11,393 10,914 
Insurance customer receivables1,488 3,199 
Other receivables691 162 
Total$26,154 
Accounts receivable, net classified as assets of businesses held for sale
(1,927)
Total$26,929 $24,227 
v3.25.1
Divestiture (Tables)
 3 Months Ended
Mar. 31, 2025
Discontinued Operations and Disposal Groups [Abstract]  
Divestiture
(In millions)December 31, 2024
Cash and cash equivalents$1,339 
Investments1,444 
Accounts receivable, net1,927 
Other assets, including Goodwill (1)
2,294 
Total assets of businesses held for sale7,004 
Insurance and contractholder liabilities1,579 
All other liabilities831 
Total liabilities of businesses held for sale$2,410 
(1) Includes Goodwill of $94 million as of December 31, 2024.
v3.25.1
Earnings Per Share (Tables)
 3 Months Ended
Mar. 31, 2025
Earnings Per Share [Abstract]  
Computation of Basic and Diluted Earnings Per Share
Basic and diluted earnings per share were computed as follows:
Three Months Ended
March 31, 2025March 31, 2024
(Shares in thousands, dollars in millions, except per share amounts)BasicEffect of
Dilution		DilutedBasicEffect of
Dilution		Diluted
Shareholders' net income (loss)
$1,323 $1,323 $(277)$(277)
Shares:
Weighted average270,867 270,867 286,465 286,465 
Common stock equivalents2,086 2,086 — — 
Total shares270,867 2,086 272,953 286,465 — 286,465 
Earnings per share$4.88 $(0.03)$4.85 $(0.97)$— $(0.97)
v3.25.1
Common and Preferred Stock (Tables)
 3 Months Ended
Mar. 31, 2025
Equity [Abstract]  
Dividend Payments
The following table provides details of the Company's dividend payments:
Record DatePayment DateAmount per Share
Total Amount Paid (in millions)
2025
March 5, 2025March 20, 2025$1.51$412
2024
March 6, 2024March 21, 2024$1.40$401
v3.25.1
Insurance and Contractholder Liabilities (Tables)
 3 Months Ended
Mar. 31, 2025
Insurance Loss Reserves [Abstract]  
Insurance and Contractholder Liabilities
The Company's insurance and contractholder liabilities were comprised of the following:
March 31, 2025December 31, 2024March 31, 2024
(In millions)CurrentNon-currentTotalCurrentNon-currentTotalTotal
Unpaid claims and claim expenses
Cigna Healthcare
$4,452 $56 $4,508 $4,932 $86 $5,018 $5,863 
Other172 194 366 147 144 291 260 
Future policy benefits
Cigna Healthcare
38 154 192 91 507 598 607 
Other Operations151 3,157 3,308 157 3,140 3,297 3,460 
Contractholder deposit funds
Cigna Healthcare
— — — 9 115 124 141 
Other Operations348 5,903 6,251 366 5,958 6,324 6,452 
Market risk benefits30 800 830 25 760 785 891 
Unearned premiums793 45 838 753 31 784 836 
Total6,480 10,741 17,221 18,510
Insurance and contractholder liabilities classified as liabilities of businesses held for sale (1)
(1,092)(487)(1,579)(2,081)
Total insurance and contractholder liabilities$5,984 $10,309 $16,293 $5,388 $10,254 $15,642 $16,429 
(1) Amounts classified as liabilities of businesses held for sale include $983 million of Unpaid claims, $408 million of Future policy benefits, $85 million of Unearned premiums and $103 million of Contractholder deposit funds as of December 31, 2024 and $1,378 million of Unpaid claims, $427 million of Future policy benefits, $161 million of Unearned premiums and $115 million of Contractholder deposit funds as of March 31, 2024.
Activity, net of intercompany transactions, in the unpaid claims liability for the Cigna Healthcare segment was as follows:
Three Months Ended March 31,
(In millions)
2025 (1)
2024 (1)
Beginning balance$5,018 $5,092 
Less: Reinsurance and other amounts recoverable159 236 
Beginning balance, net4,859 4,856 
Incurred costs related to:
Current year10,606 9,452 
Prior years(222)(226)
Total incurred10,384 9,226 
Paid costs related to:
Current year6,078 5,072 
Prior years3,472 3,352 
Total paid9,550 8,424 
Less: Divestiture and other1,323 — 
Ending balance, net4,370 5,658 
Add: Reinsurance and other amounts recoverable138 205 
Ending balance$4,508 $5,863 
(1) Includes unpaid claims amounts classified as liabilities of businesses held for sale prior to the completion of the HCSC transaction. As of December 31, 2024, March 31, 2024 and December 31, 2023, includes $983 million and $1,378 million, $823 million classified as liabilities of businesses held for sale, respectively.
Variances in Incurred Costs Related to Prior Years' Unpaid Claims and Claims Expenses
Variances in incurred costs related to prior years' unpaid claims and claim expenses that resulted from the differences between actual experience and the Company's key assumptions were as follows:
Three Months Ended March 31,
20252024
(Dollars in millions)$
% (1)
$
% (2)
Actual completion factors and other
$96 0.3 %$76 0.2 %
Medical cost trend126 0.3 150 0.4 
Total favorable variance$222 0.6 %$226 0.6 %
(1)Percentage of current year incurred costs as reported for the year ended December 31, 2024.
(2)Percentage of current year incurred costs as reported for the year ended December 31, 2023.
Future Policy Benefit Activity
The weighted average interest rates applied and duration for future policy benefits in Other Operations, consisting of annuity and life insurance products, were as follows:
As of
March 31, 2025March 31, 2024
Interest accretion rate 5.64 %5.64 %
Current discount rate 5.30 %5.16 %
Weighted average duration 10.8 years11.3 years
Summary of Market Risk Benefit
Market risk benefits activity was as follows:
Three Months Ended March 31,
(In millions)20252024
Balance, beginning of year$785 $1,003 
Balance, beginning of year, before the effect of nonperformance risk (own credit risk)838 1,085 
Changes due to expected run-off(4)(3)
Changes due to capital markets versus expected44 (113)
Changes due to policyholder behavior versus expected— (14)
Balance, end of period, before the effect of changes in nonperformance risk (own credit risk)878 955 
Nonperformance risk (own credit risk), end of period(48)(64)
Balance, end of period$830 $891 
Reinsured market risk benefit, end of period$876 $951 
Account Value, Net Amount at Risk and the Number of Contractholders for Guarantees Assumed in the Event of Death
The following table presents the net amount at risk and the average attained age of contractholders (weighted by exposure) for contracts assumed by the Company. The net amount at risk is the amount the Company would have to pay to contractholders if all deaths or annuitizations occurred as of the earliest possible date in accordance with the insurance contract. The Company should be reimbursed in full for these payments unless the Berkshire reinsurance limit is exceeded, as discussed further in Note 10 to the Consolidated Financial Statements.
(Dollars in millions, excludes impact of reinsurance ceded)March 31, 2025March 31, 2024
Net amount at risk$1,412 $1,441 
Average attained age of contractholders (weighted by exposure)77.0 years77.7 years
v3.25.1
Reinsurance (Tables)
 3 Months Ended
Mar. 31, 2025
Reinsurance Disclosures [Abstract]  
Reinsurance Recoverables The Company's reinsurance recoverables as of March 31, 2025 are presented at amount due by range of external credit rating and collateral level in the following table, with reinsurance recoverables that are market risk benefits separately presented at fair value:
(In millions)
Fair Value of Collateral Contractually Required to Meet or Exceed Carrying Value of Recoverable
Collateral Provisions Exist That May Mitigate Risk of Credit Loss (1)
No CollateralTotal
Ongoing operations
A- equivalent and higher current ratings (2)
$— $6 $177 $183 
BBB- to BBB+ equivalent current credit ratings (2)
— — 63 63 
Not rated101 3 3 107 
Acquisition, disposition or run-off activities
BBB+ equivalent and higher current ratings (2)(3)
304 2,804 208 3,316 
Not rated— 6 1 7 
Total reinsurance recoverables before market risk benefits$405 $2,819 $452 $3,676 
Allowance for uncollectible reinsurance(31)
Market risk benefits876 
Total reinsurance recoverables (4)
$4,521 
(1)Includes collateral provisions requiring the reinsurer to fully collateralize its obligation if its external credit rating is downgraded to a specified level.
(2)Certified by a nationally recognized statistical ratings organization ("NRSRO").
(3)Comprised of six reinsurers of which 75% is held by two reinsurers, Lincoln National Life Insurance Company and Lincoln Life and Annuity Company of New York.
(4)Includes $146 million of current reinsurance recoverables that are reported in Other current assets.
v3.25.1
Investments (Tables)
 3 Months Ended
Mar. 31, 2025
Investments [Abstract]  
Investments by category and current or long-term classification
The following table summarizes the Company's investments by category and current or long-term classification:
March 31, 2025December 31, 2024
(In millions)CurrentLong-TermTotalCurrentLong-TermTotal
Debt securities$454 $7,761 $8,215 $463 $8,960 $9,423 
Equity securities11 548 559 7 554 561 
Commercial mortgage loans66 1,228 1,294 108 1,243 1,351 
Policy loans— 1,128 1,128 — 1,156 1,156 
Other long-term investments— 4,685 4,685 — 4,576 4,576 
Short-term investments196 — 196 170 — 170 
Total$748 $16,489 $17,237 
Investments classified as assets of businesses held for sale (1)
(83)(1,361)(1,444)
Investments per Consolidated Balance Sheets$727 $15,350 $16,077 $665 $15,128 $15,793 
(1) Investments related to the HCSC transaction that were held for sale as of December 31, 2024. These investments were primarily comprised of debt securities.
Debt Securities by Contractual Maturity
The amortized cost and fair value by contractual maturity periods for debt securities were as follows as of March 31, 2025:
(In millions)Amortized
Cost		Fair
Value
Due in one year or less$622 $555 
Due after one year through five years3,334 3,224 
Due after five years through ten years2,388 2,270 
Due after ten years2,036 1,837 
Mortgage and other asset-backed securities357 329 
Total$8,737 $8,215 
Gross Unrealized Appreciation (Depreciation) on Debt Securities
Gross unrealized appreciation (depreciation) on debt securities by type of issuer is shown below:
(In millions)Amortized
Cost		Allowance for Credit LossUnrealized
Appreciation		Unrealized
Depreciation		Fair
Value
March 31, 2025
Federal government and agency$211 $— $16 $(4)$223 
State and local government24 — 1 — 25 
Foreign government359 — 8 (9)358 
Corporate7,786 (107)116 (515)7,280 
Mortgage and other asset-backed357 — 2 (30)329 
Total$8,737 $(107)$143 $(558)$8,215 
December 31, 2024
Federal government and agency$276 $— $14 $(9)$281 
State and local government37 — 1 (1)37 
Foreign government350 — 5 (11)344 
Corporate9,091 (111)102 (659)8,423 
Mortgage and other asset-backed371 — 1 (34)338 
Total$10,125 $(111)$123 $(714)$9,423 
Summary of Debt Securities with a Decline in Fair Value
The table below summarizes debt securities with a decline in fair value from amortized cost for which an allowance for credit losses has not been recorded (by investment grade and the length of time these securities have been in an unrealized loss position). Unrealized depreciation on these debt securities is primarily due to declines in fair value resulting from increasing interest rates since these securities were purchased.
March 31, 2025December 31, 2024
(Dollars in millions)Fair
Value		Amortized
Cost		Unrealized
Depreciation		Number
of Issues		Fair
Value		Amortized
Cost		Unrealized
Depreciation		Number
of Issues
One year or less
Investment grade$567 $573 $(6)353$1,203 $1,227 $(24)545 
Below investment grade220 228 (8)802245 250 (5)739 
More than one year
Investment grade3,818 4,319 (501)1,0804,687 5,319 (632)1,297 
Below investment grade325 368 (43)107416 469 (53)123 
Total$4,930 $5,488 $(558)2,342 $6,551 $7,265 $(714)2,704 
Equity Security Investments
The following table provides the values of the Company's equity security investments:
March 31, 2025 December 31, 2024
(In millions) CostCarrying Value CostCarrying Value
Equity securities with readily determinable fair values$637 $38 $635 $37 
Equity securities with no readily determinable fair value3,217 521 3,215 524 
Total$3,854 $559 $3,850 $561 
Summary of the Credit Risk Profile of the Commercial Mortgage Loan Portfolio
The following table summarizes the credit risk profile of the Company's commercial mortgage loan portfolio:

(Dollars in millions)March 31, 2025December 31, 2024
Loan-to-Value RatioCarrying ValueAverage Debt Service Coverage RatioAverage Loan-to-Value RatioCarrying ValueAverage Debt Service Coverage RatioAverage Loan-to-Value Ratio
Below 60%$503 2.05$547 2.07
60% to 79%628 1.71595 1.83
80% to 100%163 0.88209 0.51
Total$1,294 1.7269 %$1,351 1.7069 %
Carrying Value Information for Other Long-Term Investments
Other long-term investments include investments in unconsolidated entities, including certain limited partnerships and limited liability companies holding real estate, securities or loans. These investments are carried at cost plus the Company's ownership percentage of reporting income or loss, based on the financial statements of the underlying investments that are generally reported at fair value. Income or loss from these investments is reported on a one quarter lag due to the timing of when financial information is received from the general partner or manager of the investments.
Other long-term investments also include investment real estate carried at depreciated cost less any impairment write-downs to fair value when cash flow estimates indicate that the carrying value may not be recoverable. Additionally, statutory and other restricted deposits and foreign currency swaps carried at fair value are reported in the table below as Other. The following table provides the carrying value information for these investments:
Carrying Value as of
(In millions)March 31, 2025December 31, 2024
Real estate investments$1,808 $1,763 
Securities partnerships2,660 2,587 
Other217 226 
Total$4,685 $4,576 
v3.25.1
Fair Value Measurements (Tables)
 3 Months Ended
Mar. 31, 2025
Fair Value Disclosures [Abstract]  
Financial Assets and Financial Liabilities Carried at Fair Value
The following table provides information about the Company's financial assets and liabilities carried at fair value. Further information regarding insurance assets and liabilities carried at fair value is provided in Note 9E to the Consolidated Financial Statements. Separate account assets are also recorded at fair value on the Company's Consolidated Balance Sheets and are reported separately in the Separate Accounts section below as gains and losses related to these assets generally accrue directly to contractholders.
(In millions)Quoted Prices in Active Markets for Identical Assets
(Level 1)		Significant Other Observable Inputs
(Level 2)		Significant Unobservable Inputs
(Level 3)		Total
March 31,
2025		December 31, 2024March 31,
2025		December 31, 2024March 31,
2025		December 31, 2024March 31,
2025		December 31, 2024
Financial assets at fair value
Debt securities
Federal government and agency$104 $165 $119 $116 $— $— $223 $281 
State and local government— — 25 37 — — 25 37 
Foreign government— — 358 344 — — 358 344 
Corporate
— — 6,951 8,049 329 374 7,280 8,423 
Mortgage and other asset-backed— — 285 295 44 43 329 338 
Total debt securities104 165 7,738 8,841 373 417 8,215 9,423 
Equity securities (1)
1 1 37 36 — — 38 37 
Short-term investments— — 196 170 — — 196 170 
Derivative assets— — 153 168 — — 153 168 
Financial liabilities at fair value
Derivative liabilities$— $— $2 $1 $— $— $2 $1 
(1)Excludes certain equity securities that have no readily determinable fair value.
Fair Value and Significant Unobservable Inputs Used in Pricing Debt Securities
The following table summarizes the fair value and significant unobservable inputs that were developed directly by the Company and used in pricing these debt securities. The range and weighted average basis point amounts for liquidity reflect the Company's best estimates of the unobservable adjustments a market participant would make to calculate these fair values. An increase in liquidity spread adjustments would result in a lower fair value measurement, while a decrease would result in a higher fair value measurement.

Fair Value as ofUnobservable Adjustment Range (Weighted Average by Quantity) as of
(Fair value in millions)March 31,
2025		December 31,
2024
Unobservable Input
March 31, 2025
March 31,
2025		December 31,
2024
Debt securities
Corporate$329 $373 Liquidity
5 - 1475 (300)
bps
60 - 1520 (370)
bps
Mortgage and other asset-backed securities44 43 Liquidity
105 - 575 (290)
bps
100 - 550 (280)
bps
Other debt securities— 1 
Total Level 3 debt securities$373 $417 
Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value
The following table summarizes the changes in financial assets and financial liabilities classified in Level 3. Gains and losses reported in the table may include net changes in fair value that are attributable to both observable and unobservable inputs.
Three Months Ended
March 31,
(In millions)20252024
Debt securities
Beginning balance$417 $447 
Losses included in Shareholders' net income (loss)
(10)(21)
Gains (losses) included in Other comprehensive loss
7 (3)
Purchases, sales and settlements
Purchases2 — 
Settlements(31)(14)
Total purchases, sales and settlements(29)(14)
Transfers into / (out of) Level 3
Transfers into Level 318 16 
Transfers out of Level 3(30)(3)
Total transfers into / (out of) Level 3(12)13 
Ending balance$373 $422 
Total losses included in Shareholders' net income (loss) attributable to instruments held at the reporting date
$(13)$(21)
Change in unrealized gain or (loss) included in Other comprehensive loss for assets held at the end of the reporting period
$3 $(4)
Fair Values of Separate Account Assets
Fair values of Separate account assets were as follows:
Quoted Prices in Active Markets for Identical Assets
(Level 1)		Significant Other Observable Inputs
(Level 2)		Significant Unobservable Inputs
(Level 3)		Total
(In millions)March 31,
2025		December 31,
2024		March 31,
2025		December 31,
2024		March 31,
2025		December 31,
2024		March 31,
2025		December 31,
2024
Guaranteed separate accounts (See Note 16)
$227 $231 $328 $345 $— $— $555 $576 
Non-guaranteed separate accounts (1)
275 267 5,559 5,575 255 228 6,089 6,070 
Subtotal$502 $498 $5,887 $5,920 $255 $228 6,644 6,646 
Non-guaranteed separate accounts priced at net asset value as a practical expedient (1)
633 632 
Total$7,277 $7,278 
Non-guaranteed separate accounts include $3.8 billion as of each of March 31, 2025 and December 31, 2024 in assets supporting the Company's pension plans, including $0.2 billion classified in Level 3 as of each of March 31, 2025 and December 31, 2024, respectively. Non-guaranteed separate accounts are primarily comprised of securities partnerships, real estate and real estate funds.
Fair Value Disclosures for Financial Instruments Not Carried at Fair Value
The following table includes the Company's financial instruments not recorded at fair value but for which fair value disclosure is required. In addition to universal life products and finance leases, financial instruments that are carried in the Company's Consolidated Balance Sheets at amounts that approximate fair value are excluded from the following table.
Classification in Fair Value HierarchyMarch 31, 2025December 31, 2024
(In millions)Fair ValueCarrying ValueFair ValueCarrying Value
Commercial mortgage loansLevel 3$1,228 $1,294 $1,256 $1,351 
Long-term debt, including current maturities, excluding finance leasesLevel 2$28,149 $30,371 $28,392 $31,008 
v3.25.1
Accumulated Other Comprehensive Income (Loss) (Tables)
 3 Months Ended
Mar. 31, 2025
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]  
Changes in the Components of AOCI
Changes in the components of AOCI were as follows:
Three Months Ended
March 31,
(In millions)20252024
Securities and Derivatives
Beginning balance$832 $171 
Unrealized (depreciation) appreciation on securities and derivatives, before reclassification, net of tax benefit (expense) of $49 and $(39), respectively
(134)104 
Amounts reclassified to Shareholders' net income (loss), net of tax (benefit) of $(9) and $(5), respectively
34 17 
Other comprehensive (loss) income, net of tax
(100)121 
Ending balance$732 $292 
Net long-duration insurance and contractholder liabilities measurement adjustments
Beginning balance$(2,038)$(971)
Net current period change in discount rate for certain long-duration liabilities, before reclassification, net of tax benefit of $33 and $186, respectively
(108)(546)
Amounts reclassified to Shareholders' net income (loss), net of tax expense of $16 and $—, respectively
(56)— 
Net current period change in discount rate for certain long-duration liabilities, net of tax benefit of $49 and $186, respectively
(164)(546)
Net current period change in instrument-specific credit risk for market risk benefits, net of tax benefit of $1 and $4, respectively
(4)(14)
Other comprehensive (loss), net of tax
(168)(560)
Ending balance$(2,206)$(1,531)
Translation of foreign currencies
Beginning balance$(198)$(149)
Net translation of foreign currencies, before reclassification, net of tax (expense) of $(6) and $(2), respectively
13 (26)
Ending balance$(185)$(175)
Postretirement benefits liability
Beginning balance$(937)$(915)
Amounts reclassified to Shareholders' net income, net of tax (benefit) of $(2) and $(3), respectively
6 5 
Ending balance$(931)$(910)
Total Accumulated other comprehensive loss
Beginning balance$(2,341)$(1,864)
Shareholders' other comprehensive (loss), net of tax benefit of $82 and $141, respectively
(249)(460)
Ending balance$(2,590)$(2,324)
v3.25.1
Strategic Optimization Program (Tables)
 3 Months Ended
Mar. 31, 2025
Restructuring and Related Activities [Abstract]  
Roll forward of Accrued Liability
The following table summarizes a roll forward of the accrued liability recorded in Accrued expenses and other liabilities during the three months ended March 31, 2025:
(In millions)
Balance, December 31, 2024
$— 
First quarter 2025 charge
171 
2025 payments
(10)
Balance, March 31, 2025
$161 
v3.25.1
Segment Information (Tables)
 3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Summary of Special Items
The following table presents the special items charges (benefits) recorded by the Company, as well as the respective financial statement line items impacted:
Three Months Ended March 31,
20252024
(In millions)Pre-taxAfter-taxPre-taxAfter-tax
Integration and transaction-related costs (Selling, general and administrative expenses)$216 $164 $37 $29 
Strategic optimization program (primarily Selling, general and administrative expenses)215 163 — — 
Deferred tax expenses, net (Income taxes, less amount attributable to noncontrolling interests)— 17 — 17 
(Gain) loss on sale of businesses (41)(115)19 (43)
Total impact from special items$390 $229 $56 $3 
Summarized Segment Financial Information
Summarized segment financial information was as follows:
(In millions)
Evernorth Health Services
Cigna Healthcare
Other Operations
Corporate and Eliminations
Total
Three months ended March 31, 2025
Revenues from external customers$52,002 $13,168 $94 $— $65,264 
Intersegment revenues1,648 1,231 12 (2,891)
Net investment income
31 133 69 5 238 
Total revenues53,681 14,532 175 (2,886)65,502 
Net investment results from certain equity method investments
— (50)— — (50)
Adjusted revenues$53,681 $14,482 $175 $(2,886)$65,452 
Pharmacy and other service costs51,121 — 
Medical costs— 10,385 
Selling, general and administrative expenses1,024 2,812 
Other segment items (1)
   Interest (expense) and other— 2 
   Less: Income attributable to noncontrolling interests102 — 
Pre-tax adjusted income (loss) from operations1,434 1,287 — (411)2,310 
Income (loss) before income taxes
$1,108 $1,364 $(20)$(804)$1,648 
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) attributable to noncontrolling interests
(102)— — — (102)
Net investment (gains) losses (2)
(4)(47)3 — (48)
Amortization of acquired intangible assets415 7 — — 422 
Special items
Integration and transaction-related costs— — — 216 216 
Strategic optimization program21 — 17 177 215 
(Gain) on sale of businesses(4)(37)— — (41)
Pre-tax adjusted income (loss) from operations$1,434 $1,287 $— $(411)$2,310 
Other segment information
Depreciation and amortization$584 $83 $2 $5 $674 
(1)Other segment items represent the difference between segment adjusted revenues less significant segment expenses and pre-tax adjusted income (loss) from operations, and they do not represent significant segment items relative to the CODM's review and oversight.
(2)Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.
(In millions)
Evernorth Health Services
Cigna Healthcare
Other Operations
Corporate and Eliminations
Total
Three months ended March 31, 2024
Revenues from external customers $44,886 $12,012 $66 $1 $56,965 
Intersegment revenues1,281 1,124 25 (2,430)
Net investment income
59 149 75 7 290 
Total revenues46,226 13,285 166 (2,422)57,255 
Net investment results from certain equity method investments— (8)— — (8)
Adjusted revenues$46,226 $13,277 $166 $(2,422)$57,247 
Pharmacy and other service costs43,838 — 
Medical costs— 9,219 
Selling, general and administrative expenses951 2,720 
Other segment items (1)
Interest (expense) and other— 2 
Less: income attributable to noncontrolling interests77 — 
Pre-tax adjusted income (loss) from operations1,360 1,340 18 (409)2,309 
(Loss) income before income taxes
$(436)$943 $18 $(446)$79 
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) attributable to noncontrolling interests
(77)— — — (77)
Net investment losses (2)
1,456 372 — — 1,828 
Amortization of acquired intangible assets417 6 — — 423 
Special items
Integration and transaction-related costs
— — — 37 37 
Loss on sale of businesses
— 19 — — 19 
Pre-tax adjusted income (loss) from operations$1,360 $1,340 $18 $(409)$2,309 
Other segment information
Depreciation and amortization$606 $124 $1 $10 $741 
(1)Other segment items represent the difference between segment adjusted revenues less significant segment expenses and pre-tax adjusted income (loss) from operations, and they do not represent significant segment items relative to the CODM's review and oversight.
(2)Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.
Revenue from External Customers
Revenue from external customers includes Pharmacy revenues, Premiums and Fees and other revenues. The following table presents these revenues by product, premium and service type:
Three Months Ended March 31,
(In millions)20252024
Products (Pharmacy revenues) (ASC 606)
Network revenues$28,212 $24,166 
Home delivery and specialty revenues18,937 16,458 
Other revenues3,077 2,546 
Total Evernorth Health Services
50,226 43,170 
Other Operations
13 17 
Corporate and eliminations(1,606)(1,151)
Total Pharmacy revenues
48,633 42,036 
Insurance premiums (ASC 944)
Cigna Healthcare
U.S. Healthcare
Employer insured4,688 4,393 
Medicare Advantage2,363 2,287 
Stop loss1,868 1,668 
Individual and Family Plans859 1,040 
Other1,872 1,258 
U.S. Healthcare
11,650 10,646 
International Health978 885 
Total Cigna Healthcare12,628 11,531 
Other Operations81 48 
Corporate and eliminations27 24 
Total Premiums
12,736 11,603 
Services (Fees) (ASC 606) and Other revenues (1)
Evernorth Health Services
3,424 2,997 
Cigna Healthcare
1,771 1,605 
Other Operations
12 26 
Corporate and eliminations(1,312)(1,302)
Total Fees and other revenues (1)
3,895 3,326 
Total revenues from external customers$65,264 $56,965 
(1)Other revenues for the three months ended March 31, 2025 and 2024 were $162 million and $90 million, respectively.
v3.25.1
Accounts Receivable, Net - Amounts (Details) - USD ($)
$ in Millions
Mar. 31, 2025
Dec. 31, 2024
Receivables [Abstract]    
Noninsurance customer receivables $ 13,357  
Pharmaceutical manufacturer receivables 11,393  
Insurance customer receivables 1,488  
Other receivables 691  
Accounts receivable, net $ 26,929 $ 24,227
v3.25.1
Accounts Receivable, Net - Amounts, Including Disposal Groups (Details) - USD ($)
$ in Millions
Mar. 31, 2025
Dec. 31, 2024
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Noninsurance customer receivables, including held for sale assets   $ 11,879
Pharmaceutical manufacturers receivable, including held for sale assets   10,914
Insurance customer receivables, including held for sale assets   3,199
Other receivables, including held for sale assets   162
Total   26,154
Accounts receivable, net $ 26,929 24,227
Held-for-Sale | Medicare Advantage and related Cigna Healthcare businesses    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Accounts receivable, net classified as assets of businesses held for sale   $ (1,927)
v3.25.1
Accounts Receivable, Net - Allowances (Details) - USD ($)
$ in Millions
Mar. 31, 2025
Dec. 31, 2024
Receivables [Abstract]    
Allowance for receivables, current $ 5,700 $ 5,000
Allowance for current expected credit losses on accounts receivable $ 296 $ 84
v3.25.1
Accounts Receivable, Net - Factoring Facility (Details) - USD ($)
 1 Months Ended 3 Months Ended
Jul. 31, 2023
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Receivables [Abstract]        
Initial term, uncommitted factoring facility (in years) 2 years      
Automatic renewal term, uncommitted factoring facility (in years) 1 year      
Total capacity, uncommitted factoring facility   $ 1,500,000,000    
Accounts receivable sold, uncommitted factoring facility   1,400,000,000 $ 1,900,000,000  
Accounts receivable sold that remain outstanding, uncommitted factoring facility   0   $ 0
Accounts receivable received but not remitted, uncommitted factoring facility   $ 0   $ 1,000,000,000.0
v3.25.1
Supplier Finance Program (Details) - USD ($)
$ in Millions
Mar. 31, 2025
Dec. 31, 2024
Payables and Accruals [Abstract]    
Supplier Finance Program, Obligation, Statement of Financial Position [Extensible Enumeration] Accounts payable Accounts payable
Supplier Finance Program, Obligation, Current, Statement of Financial Position [Extensible Enumeration] Accounts payable Accounts payable
Outstanding payment obligations, supplier finance program $ 1,600 $ 1,600
Outstanding payment obligations, current 1,600 $ 1,600
Outstanding payment obligations, current, voluntarily elected by suppliers to be sold to the financial institution $ 563  
v3.25.1
Divestiture (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 19, 2025
Dec. 31, 2025
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Jan. 31, 2024
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax [Abstract]            
Loss on sale of businesses, location, Consolidated Statements of Income     Gain (loss) on sale of businesses      
Disposal Group, Including Discontinued Operation, Balance Sheet Disclosures [Abstract]            
Integration and transaction-related costs     $ 216 $ 37    
Integration and transaction-related costs, after-tax     164 29    
Disposed of by Sale | Medicare Advantage and related Cigna Healthcare businesses | Health Care Service Corporation (HCSC)            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]            
Cash proceeds from sale of business $ 4,200          
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax [Abstract]            
Estimated loss on sale, pre-tax     37      
Estimated loss on sale, after-tax     $ 112      
Disposed of by Sale | Medicare Advantage and related Cigna Healthcare businesses | Health Care Service Corporation (HCSC) | Forecast            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]            
Cash proceeds from sale of business   $ 600        
Held-for-Sale | Medicare Advantage and related Cigna Healthcare businesses            
Disposal Group, Including Discontinued Operation, Balance Sheet Disclosures [Abstract]            
Cash and cash equivalents         $ 1,339  
Investments         1,444  
Accounts receivable, net         1,927  
Other assets, including Goodwill         2,294  
Goodwill classified as Assets of businesses held for sale         94  
Total assets of businesses held for sale         7,004  
Insurance and contractholder liabilities       $ 2,081 1,579  
All other liabilities         831  
Total liabilities of businesses held for sale         $ 2,410  
Held-for-Sale | Medicare Advantage and related Cigna Healthcare businesses | Health Care Service Corporation (HCSC)            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]            
Sale price $ 4,800         $ 3,300
v3.25.1
Earnings Per Share - Basic and Diluted Earnings Per Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Earnings Per Share [Abstract]    
Shareholders' net income $ 1,323 $ (277)
Shares:    
Weighted average 270,867 286,465
Common stock equivalents 2,086 0
Total shares 272,953 286,465
Earnings per share, basic $ 4.88 $ (0.97)
Earnings per share, effect of dilution (0.03) 0
Earnings per share, diluted $ 4.85 $ (0.97)
v3.25.1
Earnings Per Share - Anti-dilutive Options (Details) - shares
shares in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Employee Stock Options    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive options 2.3 8.2
v3.25.1
Earnings Per Share - Shares of Common Stock Held in Treasury (Details) - shares
shares in Millions
Mar. 31, 2025
Dec. 31, 2024
Mar. 31, 2024
Earnings Per Share [Abstract]      
Shares of common stock held in treasury 134.1 128.7 117.8
v3.25.1
Debt - Debt Issuance and Debt Tender Offers (Details) - USD ($)
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Debt Instrument [Line Items]    
Repayment of long-term debt $ 700,000,000 $ 2,210,000,000
$700 million, 5.685% Notes due 2026 | Senior Notes    
Debt Instrument [Line Items]    
Interest rate 5.685%  
Principal amount redeemed $ 700,000,000  
v3.25.1
Debt - Revolving Credit Agreements (Details) - USD ($)
 1 Months Ended
Apr. 30, 2025
Mar. 31, 2025
Debt Instrument [Line Items]    
Outstanding balances   $ 0
Commercial paper   0
Commercial Paper    
Debt Instrument [Line Items]    
Maximum borrowing capacity   $ 6,500,000,000
Revolving Credit Agreements, April 2025 | Subsequent Event    
Debt Instrument [Line Items]    
Maximum borrowing capacity $ 6,500,000,000  
Credit agreement term 5 years  
Credit agreement extension term 1 year  
Aggregate amount of options to increase commitments $ 1,500,000,000  
Maximum total commitment $ 8,000,000,000.0  
Leverage ratio covenant 60.00%  
Revolving Credit Agreements, April 2025 | Letter of Credit | Subsequent Event    
Debt Instrument [Line Items]    
Maximum borrowing capacity $ 500,000,000  
v3.25.1
Debt - Interest Expense (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Debt Disclosure [Abstract]    
Interest expense on long-term and short-term debt $ 362 $ 369
v3.25.1
Common and Preferred Stock - Dividends (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended
Apr. 23, 2025
Mar. 20, 2025
Mar. 21, 2024
Mar. 31, 2025
Mar. 31, 2024
Equity [Abstract]          
Amount per share (in dollars per share)   $ 1.51 $ 1.40    
Total amount paid   $ 412 $ 401 $ 412 $ 401
Subsequent Event [Line Items]          
Common dividends declared (in dollars per share)       $ 1.51 $ 1.40
Amount per share (in dollars per share)   $ 1.51 $ 1.40    
Total amount paid   $ 412 $ 401 $ 412 $ 401
Subsequent Event          
Subsequent Event [Line Items]          
Common dividends declared (in dollars per share) $ 1.51        
v3.25.1
Insurance and Contractholder Liabilities - Account Balances (Details) - USD ($)
$ in Millions
Mar. 31, 2025
Dec. 31, 2024
Mar. 31, 2024
Dec. 31, 2023
Current        
Market risk benefits, current $ 30 $ 25    
Unearned premiums, current 793      
Current insurance and contractholder liabilities 5,984 5,388    
Non-current        
Market risk benefits, non-current 800 760    
Unearned premiums, non-current 45      
Non-current insurance and contractholder liabilities 10,309 10,254    
Total        
Market risk benefits 830 785 $ 891  
Unearned premiums 838      
Total insurance and contractholder liabilities 16,293 15,642 16,429  
Cigna Healthcare        
Current        
Unpaid claims and claim expenses, current 4,452      
Future policy benefits, current 38      
Contractholder deposit funds, current 0      
Non-current        
Unpaid claims and claim expenses, non-current 56      
Future policy benefits, non-current 154      
Contractholder deposit funds, non-current 0      
Total        
Unpaid claims and claim expenses 4,508      
Total liability for future policy benefits 192      
Contractholder deposit funds 0      
Other        
Current        
Unpaid claims and claim expenses, current 172 147    
Non-current        
Unpaid claims and claim expenses, non-current 194 144    
Total        
Unpaid claims and claim expenses 366 291 260  
Other Operations        
Current        
Future policy benefits, current 151 157    
Contractholder deposit funds, current 348 366    
Non-current        
Future policy benefits, non-current 3,157 3,140    
Contractholder deposit funds, non-current 5,903 5,958    
Total        
Total liability for future policy benefits 3,308 3,297 3,460  
Contractholder deposit funds $ 6,251 $ 6,324 $ 6,452 $ 6,500
v3.25.1
Insurance and Contractholder Liabilities - Account Balances including Disposal Groups (Details) - USD ($)
$ in Millions
Mar. 31, 2025
Dec. 31, 2024
Mar. 31, 2024
Dec. 31, 2023
Current        
Market risk benefits, current $ 30 $ 25    
Unearned premiums, current, including held for sale liabilities   753    
Total, including held for sale liabilities, current   6,480    
Current insurance and contractholder liabilities 5,984 5,388    
Non-current        
Market risk benefits, non-current 800 760    
Unearned premiums, non-current, including held for sale liabilities   31    
Total, including liabilities held for sale, non-current   10,741    
Non-current insurance and contractholder liabilities 10,309 10,254    
Total        
Market risk benefits 830 785 $ 891  
Unearned premiums, including held for sale liabilities   784 836  
Total, including held for sale liabilities   17,221 18,510  
Total insurance and contractholder liabilities $ 16,293 15,642 16,429  
Held-for-Sale | Medicare Advantage and related Cigna Healthcare businesses        
Current        
Insurance and contractholder liabilities current, classified as held for sale   (1,092)    
Non-current        
Insurance and contractholder liabilities, non-current, classified as held for sale   (487)    
Total        
Insurance and contractholder liabilities classified as held for sale   (1,579) (2,081)  
Unpaid claims classified as liabilities of business held for sale   983 1,378 $ 823
Unearned premiums classified as liabilities of business held for sale   85 161  
Contractholder deposit funds classified as liabilities held for sale   103 115  
Cigna Healthcare        
Current        
Unpaid claims and claim expenses, current, including held for sale liabilities   4,932    
Future policy benefits, current, including held for sale liabilities   91    
Contractholder deposit funds, current, including held for sale liabilities   9    
Non-current        
Unpaid claims and claim expenses, non-current, including held for sale liabilities   86    
Future policy benefits, non-current, including held for sale liabilities   507    
Contractholder deposit funds, non-current, including liabilities held for sale   115    
Total        
Unpaid claims and claim expenses, including held for sale liabilities   5,018 5,863 $ 5,092
Future policy benefits, including held for sale liabilities   598 607  
Contractholder deposit funds, including liabilities held for sale   124 141  
Cigna Healthcare | Held-for-Sale | Medicare Advantage and related Cigna Healthcare businesses        
Total        
Future policy benefits classified as liabilities of business held for sale   $ 408 $ 427  
v3.25.1
Insurance and Contractholder Liabilities - Unpaid Claims and Claim Expenses - Cigna Healthcare - Activity (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Dec. 31, 2023
Held-for-Sale | Medicare Advantage and related Cigna Healthcare businesses        
Paid costs related to:        
Unpaid claims classified as liabilities of business held for sale   $ 1,378 $ 983 $ 823
Cigna Healthcare        
Liability for Claims and Claims Adjustment Expense [Line Items]        
Total of incurred but not reported liabilities plus expected claim development on reported claims and reported claims in process $ 4,400 5,400    
Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]        
Beginning balance, including held for sale liabilities 5,018 5,092    
Less: Reinsurance, including held for sale liabilities 159 236    
Beginning balance, net, including held for sale liabilities 4,859 4,856    
Incurred costs related to:        
Current year 10,606 9,452    
Prior years (222) (226)    
Total incurred 10,384 9,226    
Paid costs related to:        
Current year 6,078 5,072    
Prior years 3,472 3,352    
Total paid 9,550 8,424    
Less: Divestiture and other 1,323 0    
Ending balance, net 4,370      
Add: Reinsurance and other amounts recoverable 138      
Ending balance $ 4,508      
Ending balance, net, including held for sale liabilities   5,658    
Add: Reinsurance, including held for sale liabilities   205    
Ending balance, including held for sale liabilities   $ 5,863    
v3.25.1
Insurance and Contractholder Liabilities - Unpaid Claims and Claims Expenses - Cigna Healthcare - Variances in Incurred Costs Related to Prior Years' Unpaid Claims and Claims Expenses (Details) - Cigna Healthcare - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Abstract]    
Favorable (unfavorable) variance, amount $ 222 $ 226
Favorable (unfavorable) variance, percentage 0.60% 0.60%
Actual completion factors and other    
Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Abstract]    
Favorable (unfavorable) variance, amount $ 96 $ 76
Favorable (unfavorable) variance, percentage 0.30% 0.20%
Medical cost trend    
Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Abstract]    
Favorable (unfavorable) variance, amount $ 126 $ 150
Favorable (unfavorable) variance, percentage 0.30% 0.40%
v3.25.1
Insurance and Contractholder Liabilities - Future Policy Benefits - Interest Rates and Duration (Details) - Other Operations - Life and annuity insurance products
Mar. 31, 2025
Mar. 31, 2024
Insurance and Contractholder Liabilities [Line Items]    
Interest accretion rate 5.64% 5.64%
Current discount rate 5.30% 5.16%
Weighted average duration 10 years 9 months 18 days 11 years 3 months 18 days
v3.25.1
Insurance and Contractholder Liabilities - Future Policy Benefits - Present Values of Expected Premiums and Benefits (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Dec. 31, 2023
Cigna Healthcare        
Insurance and Contractholder Liabilities [Line Items]        
Liability for Future Policy Benefit, Expected Net Premium, Period Increase (Decrease)    
Liability for Future Policy Benefit, Expected Future Policy Benefit, Period Increase (Decrease)    
Other Operations        
Insurance and Contractholder Liabilities [Line Items]        
Deferred profit liability included in future policy benefits 359 379    
Future policy benefit, excluding deferred profit liability 3,000 3,100 $ 2,900 $ 3,200
Undiscounted expected future policy benefits 4,300 4,400    
Future policy benefits reserve, reinsurance recoverables $ 900 $ 1,000    
v3.25.1
Insurance and Contractholder Liabilities - Contractholder Deposit Funds (Details) - USD ($)
$ in Millions
Mar. 31, 2025
Dec. 31, 2024
Mar. 31, 2024
Dec. 31, 2023
Cigna Healthcare        
Insurance and Contractholder Liabilities [Line Items]        
Contractholder deposit funds $ 0      
Other Operations        
Insurance and Contractholder Liabilities [Line Items]        
Contractholder deposit funds $ 6,251 $ 6,324 $ 6,452 $ 6,500
Contractholder deposit fund liabilities, approximate percent reinsured externally 38.00%      
Weighted average crediting rate 3.20%   3.33%  
Net amount at risk $ 2,800   $ 3,000  
Cash surrender value $ 2,800   $ 2,800  
Other Operations | Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0300 To 0400        
Insurance and Contractholder Liabilities [Line Items]        
Contractholder deposit funds not reinsured externally, percent with guaranteed interest rates of 0300 to 0400 99.00%   99.00%  
Contractholder deposit funds not reinsured externally $ 4,000   $ 4,000  
Other Operations | Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0300 To 0400 | Policyholder Account Balance, at Guaranteed Minimum Crediting Rate        
Insurance and Contractholder Liabilities [Line Items]        
Contractholder deposit funds not reinsured externally 1,200   1,200  
Other Operations | Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0300 To 0400 | Policyholder Account Balance, above Guaranteed Minimum Crediting Rate, Range from 0051 to 0150        
Insurance and Contractholder Liabilities [Line Items]        
Contractholder deposit funds not reinsured externally 1,200   1,200  
Other Operations | Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0300 To 0400 | Policyholder Account Balance, Above Guaranteed Minimum Crediting Rate, Based On Greater Of Guaranteed Minimum Cash Value Or Actual Cash Value        
Insurance and Contractholder Liabilities [Line Items]        
Contractholder deposit funds not reinsured externally $ 1,600   $ 1,600  
Percentage with cash values at more than 110% of guaranteed cash value 90.00%   90.00%  
Other Operations | Minimum | Policyholder Account Balance, above Guaranteed Minimum Crediting Rate, Range from 0051 to 0150        
Insurance and Contractholder Liabilities [Line Items]        
Basis points above guaranteed minimum crediting rate 0.0050   0.0050  
Other Operations | Minimum | Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0300 To 0400        
Insurance and Contractholder Liabilities [Line Items]        
Guaranteed minimum credit rating 3.00%   3.00%  
Other Operations | Maximum | Policyholder Account Balance, above Guaranteed Minimum Crediting Rate, Range from 0051 to 0150        
Insurance and Contractholder Liabilities [Line Items]        
Basis points above guaranteed minimum crediting rate 0.0150   0.0150  
Other Operations | Maximum | Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0300 To 0400        
Insurance and Contractholder Liabilities [Line Items]        
Guaranteed minimum credit rating 4.00%   4.00%  
v3.25.1
Insurance and Contractholder Liabilities - Market Risk Benefits (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Insurance Loss Reserves [Abstract]    
Annuitization election period 30 days  
Market Risk Benefit [Roll Forward]    
Balance, beginning of year $ 785 $ 1,003
Balance, beginning of year, before the effect of nonperformance risk (own credit risk) 838 1,085
Changes due to expected run-off (4) (3)
Changes due to capital markets versus expected 44 (113)
Changes due to policyholder behavior versus expected 0 (14)
Balance, end of period, before the effect of changes in nonperformance risk (own credit risk) 878 955
Nonperformance risk (own credit risk), end of period (48) (64)
Balance, end of period 830 891
Reinsured market risk benefit, end of period $ 876 $ 951
v3.25.1
Insurance and Contractholder Liabilities - Net Amount of Risk and Average Age of Contractholders (Details) - Variable Annuity - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Net Amount at Risk by Product and Guarantee [Line Items]    
Net amount at risk $ 1,412 $ 1,441
Average attained age of contractholders (weighted by exposure) 77 years 77 years 8 months 12 days
v3.25.1
Reinsurance - Reinsurance Recoverables (Details)
$ in Millions
 3 Months Ended
Mar. 31, 2025
USD ($)
reinsurer
Mar. 31, 2024
USD ($)
Ceded Credit Risk [Line Items]    
Reinsurance recoverables before market risk benefits $ 3,676  
Allowance for uncollectible reinsurance (31)  
Market risk benefits 876 $ 951
Total reinsurance recoverables 4,521  
Other Current Assets    
Ceded Credit Risk [Line Items]    
Total reinsurance recoverables 146  
Fair Value of Collateral Contractually Required to Meet or Exceed Carrying Value of Recoverable    
Ceded Credit Risk [Line Items]    
Reinsurance recoverables before market risk benefits 405  
Collateral provisions exist that may mitigate risk of credit loss    
Ceded Credit Risk [Line Items]    
Reinsurance recoverables before market risk benefits 2,819  
No Collateral    
Ceded Credit Risk [Line Items]    
Reinsurance recoverables before market risk benefits 452  
BBB+ equivalent and higher current ratings | Acquisition, disposition or run-off activities    
Ceded Credit Risk [Line Items]    
Reinsurance recoverables before market risk benefits $ 3,316  
Number of reinsurers | reinsurer 6  
BBB+ equivalent and higher current ratings | Acquisition, disposition or run-off activities | The Lincoln National Life Insurance Company And Lincoln Life And Annuity Of New York    
Ceded Credit Risk [Line Items]    
Number of reinsurers | reinsurer 2  
BBB+ equivalent and higher current ratings | Acquisition, disposition or run-off activities | The Lincoln National Life Insurance Company And Lincoln Life And Annuity Of New York | Reinsurer Concentration Risk | Reinsurance Recoverables, Gross, Acquisition Disposition Runoff Activities, Nationally Recognized Statistical Rating Organizations, BBB+ Or Higher    
Ceded Credit Risk [Line Items]    
Concentration percentage 75.00%  
BBB+ equivalent and higher current ratings | Acquisition, disposition or run-off activities | Fair Value of Collateral Contractually Required to Meet or Exceed Carrying Value of Recoverable    
Ceded Credit Risk [Line Items]    
Reinsurance recoverables before market risk benefits $ 304  
BBB+ equivalent and higher current ratings | Acquisition, disposition or run-off activities | Collateral provisions exist that may mitigate risk of credit loss    
Ceded Credit Risk [Line Items]    
Reinsurance recoverables before market risk benefits 2,804  
BBB+ equivalent and higher current ratings | Acquisition, disposition or run-off activities | No Collateral    
Ceded Credit Risk [Line Items]    
Reinsurance recoverables before market risk benefits 208  
A- equivalent and higher current ratings | Ongoing operations    
Ceded Credit Risk [Line Items]    
Reinsurance recoverables before market risk benefits 183  
A- equivalent and higher current ratings | Ongoing operations | Fair Value of Collateral Contractually Required to Meet or Exceed Carrying Value of Recoverable    
Ceded Credit Risk [Line Items]    
Reinsurance recoverables before market risk benefits 0  
A- equivalent and higher current ratings | Ongoing operations | Collateral provisions exist that may mitigate risk of credit loss    
Ceded Credit Risk [Line Items]    
Reinsurance recoverables before market risk benefits 6  
A- equivalent and higher current ratings | Ongoing operations | No Collateral    
Ceded Credit Risk [Line Items]    
Reinsurance recoverables before market risk benefits 177  
BBB- to BBB+ equivalent current credit ratings | Ongoing operations    
Ceded Credit Risk [Line Items]    
Reinsurance recoverables before market risk benefits 63  
BBB- to BBB+ equivalent current credit ratings | Ongoing operations | Fair Value of Collateral Contractually Required to Meet or Exceed Carrying Value of Recoverable    
Ceded Credit Risk [Line Items]    
Reinsurance recoverables before market risk benefits 0  
BBB- to BBB+ equivalent current credit ratings | Ongoing operations | Collateral provisions exist that may mitigate risk of credit loss    
Ceded Credit Risk [Line Items]    
Reinsurance recoverables before market risk benefits 0  
BBB- to BBB+ equivalent current credit ratings | Ongoing operations | No Collateral    
Ceded Credit Risk [Line Items]    
Reinsurance recoverables before market risk benefits 63  
Not rated | Ongoing operations    
Ceded Credit Risk [Line Items]    
Reinsurance recoverables before market risk benefits 107  
Not rated | Ongoing operations | Fair Value of Collateral Contractually Required to Meet or Exceed Carrying Value of Recoverable    
Ceded Credit Risk [Line Items]    
Reinsurance recoverables before market risk benefits 101  
Not rated | Ongoing operations | Collateral provisions exist that may mitigate risk of credit loss    
Ceded Credit Risk [Line Items]    
Reinsurance recoverables before market risk benefits 3  
Not rated | Ongoing operations | No Collateral    
Ceded Credit Risk [Line Items]    
Reinsurance recoverables before market risk benefits 3  
Not rated | Acquisition, disposition or run-off activities    
Ceded Credit Risk [Line Items]    
Reinsurance recoverables before market risk benefits 7  
Not rated | Acquisition, disposition or run-off activities | Fair Value of Collateral Contractually Required to Meet or Exceed Carrying Value of Recoverable    
Ceded Credit Risk [Line Items]    
Reinsurance recoverables before market risk benefits 0  
Not rated | Acquisition, disposition or run-off activities | Collateral provisions exist that may mitigate risk of credit loss    
Ceded Credit Risk [Line Items]    
Reinsurance recoverables before market risk benefits 6  
Not rated | Acquisition, disposition or run-off activities | No Collateral    
Ceded Credit Risk [Line Items]    
Reinsurance recoverables before market risk benefits $ 1  
v3.25.1
Reinsurance - Variable Annuity Reinsurance Agreement (Details) - Variable Annuity - Berkshire Hathway Life Insurance Company Of Nebraska - USD ($)
$ in Billions
 3 Months Ended 12 Months Ended
Mar. 31, 2025
Dec. 31, 2013
Ceded Credit Risk [Line Items]    
Reinsurance, Reinsured Risk, Percentage   100.00%
Remaining overall limit under reinsurance agreement $ 3.0  
Secured | Market risk benefits reinsurance recoverable, including IBNR and outstanding claims, less premiums due | Collateralization risk    
Ceded Credit Risk [Line Items]    
Concentration percentage 90.00%  
v3.25.1
Investments - Investments by Category (Details) - USD ($)
$ in Millions
Mar. 31, 2025
Dec. 31, 2024
Schedule of Investments [Line Items]    
Current investments $ 727 $ 665
Long-term investments 15,350 15,128
Total investments 16,077 $ 15,793
Debt securities    
Schedule of Investments [Line Items]    
Current investments 454  
Long-term investments 7,761  
Total investments 8,215  
Equity securities    
Schedule of Investments [Line Items]    
Current investments 11  
Long-term investments 548  
Total investments 559  
Commercial mortgage loans    
Schedule of Investments [Line Items]    
Current investments 66  
Long-term investments 1,228  
Total investments 1,294  
Policy loans    
Schedule of Investments [Line Items]    
Current investments 0  
Long-term investments 1,128  
Total investments 1,128  
Other long-term investments    
Schedule of Investments [Line Items]    
Current investments 0  
Long-term investments 4,685  
Total investments 4,685  
Short-term investments    
Schedule of Investments [Line Items]    
Current investments 196  
Long-term investments 0  
Total investments $ 196  
v3.25.1
Investments - Investments by Category, Including Disposal Groups (Details) - USD ($)
$ in Millions
Mar. 31, 2025
Dec. 31, 2024
Current    
Investments including held for sale assets   $ 748
Current investments $ 727 665
Long-term    
Investments including held for sale assets   16,489
Investments per Consolidated Balance Sheets 15,350 15,128
Total    
Investments including held for sale assets   17,237
Total investments 16,077 15,793
Held-for-Sale | Medicare Advantage and related Cigna Healthcare businesses    
Current    
Investments classified as assets of business held for sale   (83)
Long-term    
Investments classified as assets of business held for sale   (1,361)
Total    
Investments classified as assets of business held for sale   (1,444)
Debt securities    
Current    
Investments including held for sale assets   463
Current investments 454  
Long-term    
Investments including held for sale assets   8,960
Investments per Consolidated Balance Sheets 7,761  
Total    
Investments including held for sale assets   9,423
Total investments 8,215  
Equity securities    
Current    
Investments including held for sale assets   7
Current investments 11  
Long-term    
Investments including held for sale assets   554
Investments per Consolidated Balance Sheets 548  
Total    
Investments including held for sale assets   561
Total investments 559  
Commercial mortgage loans    
Current    
Investments including held for sale assets   108
Current investments 66  
Long-term    
Investments including held for sale assets   1,243
Investments per Consolidated Balance Sheets 1,228  
Total    
Investments including held for sale assets   1,351
Total investments 1,294  
Policy loans    
Current    
Investments including held for sale assets   0
Current investments 0  
Long-term    
Investments including held for sale assets   1,156
Investments per Consolidated Balance Sheets 1,128  
Total    
Investments including held for sale assets   1,156
Total investments 1,128  
Other long-term investments    
Current    
Investments including held for sale assets   0
Current investments 0  
Long-term    
Investments including held for sale assets   4,576
Investments per Consolidated Balance Sheets 4,685  
Total    
Investments including held for sale assets   4,576
Total investments 4,685  
Short-term investments    
Current    
Investments including held for sale assets   170
Current investments 196  
Long-term    
Investments including held for sale assets   0
Investments per Consolidated Balance Sheets 0  
Total    
Investments including held for sale assets   $ 170
Total investments $ 196  
v3.25.1
Investments - Debt Securities by Contractual Maturity Periods (Details)
$ in Millions
Mar. 31, 2025
USD ($)
Amortized Cost  
Due in one year or less $ 622
Due after one year through five years 3,334
Due after five years through ten years 2,388
Due after ten years 2,036
Mortgage and other asset-backed securities 357
Total 8,737
Fair Value  
Due in one year or less 555
Due after one year through five years 3,224
Due after five years through ten years 2,270
Due after ten years 1,837
Mortgage and other asset-backed securities 329
Total $ 8,215
v3.25.1
Investments - Gross Unrealized Appreciation (Depreciation) on Debt Securities by Type of Issuer (Details)
$ in Millions
Mar. 31, 2025
USD ($)
Debt Securities, Available-for-sale [Line Items]  
Amortized Cost $ 8,737
Allowance for Credit Loss (107)
Unrealized Appreciation 143
Unrealized Depreciation (558)
Fair Value 8,215
Federal government and agency  
Debt Securities, Available-for-sale [Line Items]  
Amortized Cost 211
Allowance for Credit Loss 0
Unrealized Appreciation 16
Unrealized Depreciation (4)
Fair Value 223
State and local government  
Debt Securities, Available-for-sale [Line Items]  
Amortized Cost 24
Allowance for Credit Loss 0
Unrealized Appreciation 1
Unrealized Depreciation 0
Fair Value 25
Foreign government  
Debt Securities, Available-for-sale [Line Items]  
Amortized Cost 359
Allowance for Credit Loss 0
Unrealized Appreciation 8
Unrealized Depreciation (9)
Fair Value 358
Corporate  
Debt Securities, Available-for-sale [Line Items]  
Amortized Cost 7,786
Allowance for Credit Loss (107)
Unrealized Appreciation 116
Unrealized Depreciation (515)
Fair Value 7,280
Mortgage and other asset-backed  
Debt Securities, Available-for-sale [Line Items]  
Amortized Cost 357
Allowance for Credit Loss 0
Unrealized Appreciation 2
Unrealized Depreciation (30)
Fair Value $ 329
v3.25.1
Investments - Gross Unrealized Appreciation (Depreciation) on Debt Securities by Type of Issuer, Including Disposal Groups (Details)
$ in Millions
Dec. 31, 2024
USD ($)
Debt Securities, Available-for-sale [Line Items]  
Amortized cost, including held for sale assets $ 10,125
Allowance for Credit Loss, including held for sale assets (111)
Unrealized Appreciation, including held for sale assets 123
Unrealized Depreciation, including held for sale assets (714)
Fair Value, including held for sale assets 9,423
Federal government and agency  
Debt Securities, Available-for-sale [Line Items]  
Amortized cost, including held for sale assets 276
Allowance for Credit Loss, including held for sale assets 0
Unrealized Appreciation, including held for sale assets 14
Unrealized Depreciation, including held for sale assets (9)
Fair Value, including held for sale assets 281
State and local government  
Debt Securities, Available-for-sale [Line Items]  
Amortized cost, including held for sale assets 37
Allowance for Credit Loss, including held for sale assets 0
Unrealized Appreciation, including held for sale assets 1
Unrealized Depreciation, including held for sale assets (1)
Fair Value, including held for sale assets 37
Foreign government  
Debt Securities, Available-for-sale [Line Items]  
Amortized cost, including held for sale assets 350
Allowance for Credit Loss, including held for sale assets 0
Unrealized Appreciation, including held for sale assets 5
Unrealized Depreciation, including held for sale assets (11)
Fair Value, including held for sale assets 344
Corporate  
Debt Securities, Available-for-sale [Line Items]  
Amortized cost, including held for sale assets 9,091
Allowance for Credit Loss, including held for sale assets (111)
Unrealized Appreciation, including held for sale assets 102
Unrealized Depreciation, including held for sale assets (659)
Fair Value, including held for sale assets 8,423
Mortgage and other asset-backed  
Debt Securities, Available-for-sale [Line Items]  
Amortized cost, including held for sale assets 371
Allowance for Credit Loss, including held for sale assets 0
Unrealized Appreciation, including held for sale assets 1
Unrealized Depreciation, including held for sale assets (34)
Fair Value, including held for sale assets $ 338
v3.25.1
Investments - Summary of Debt Securities with a Decline in Fair Value (Details)
$ in Millions
Mar. 31, 2025
USD ($)
position
Total  
Fair Value $ 4,930
Total Amortized Cost 5,488
Unrealized Depreciation $ (558)
Number of Issues | position 2,342
Investment grade | Debt securities  
One year or less  
Fair Value $ 567
Amortized Cost 573
Unrealized Depreciation $ (6)
Number of Issues | position 353
More than one year  
Fair Value $ 3,818
Amortized Cost 4,319
Unrealized Depreciation $ (501)
Number of Issues | position 1,080
Below investment grade | Debt securities  
One year or less  
Fair Value $ 220
Amortized Cost 228
Unrealized Depreciation $ (8)
Number of Issues | position 802
More than one year  
Fair Value $ 325
Amortized Cost 368
Unrealized Depreciation $ (43)
Number of Issues | position 107
v3.25.1
Investments - Debt Securities with a Decline in Fair Value, Including Disposal Groups (Details)
$ in Millions
Dec. 31, 2024
USD ($)
position
Total  
Total Fair Value, including held for sale assets $ 6,551
Total Amortized Cost, including held for sale assets 7,265
Total Unrealized Depreciation, including held for sale assets $ (714)
Total Number of Issues, including held for sale assets | position 2,704
Investment grade | Debt securities  
One year or less  
Fair Value, including held for sale assets $ 1,203
Amortized Cost, including held for sale assets 1,227
Unrealized Depreciation, including held for sale assets $ (24)
Number of Issues, including held for sale assets | position 545
More than one year  
Fair Value, including held for sale assets $ 4,687
Amortized Cost, including held for sale assets 5,319
Unrealized Depreciation, including held for sale assets $ (632)
Number of Issues, including held for sale assets | position 1,297
Below investment grade | Debt securities  
One year or less  
Fair Value, including held for sale assets $ 245
Amortized Cost, including held for sale assets 250
Unrealized Depreciation, including held for sale assets $ (5)
Number of Issues, including held for sale assets | position 739
More than one year  
Fair Value, including held for sale assets $ 416
Amortized Cost, including held for sale assets 469
Unrealized Depreciation, including held for sale assets $ (53)
Number of Issues, including held for sale assets | position 123
v3.25.1
Investments - Equity Securities (Details) - USD ($)
$ in Millions
 2 Months Ended
Mar. 31, 2024
Mar. 31, 2025
Dec. 31, 2024
Cost      
Equity securities with readily determinable fair values   $ 637 $ 635
Equity securities with no readily determinable fair value   3,217 3,215
Total   3,854 3,850
Carrying Value      
Equity securities with readily determinable fair values   38 37
Equity securities with no readily determinable fair value   521 524
Total   $ 559 $ 561
VillageMD      
Carrying Value      
Amount of impairments or value changes resulting from observable price changes on equity securities with no readily available fair value still held $ 1,800    
v3.25.1
Investments - Commercial Mortgage Loans (Details) - Real Estate Loan - Commercial Portfolio Segment
$ in Millions
 3 Months Ended
Mar. 31, 2025
USD ($)
Schedule of Investments [Line Items]  
Carrying value, after allowance for credit loss $ 1,294
Weighted Average  
Schedule of Investments [Line Items]  
Average Debt Service Coverage Ratio 1.72
Average Loan-to-Value Ratio 69.00%
Below 60%  
Schedule of Investments [Line Items]  
Carrying value, after allowance for credit loss $ 503
Below 60% | Weighted Average  
Schedule of Investments [Line Items]  
Average Debt Service Coverage Ratio 2.05
60% to 79%  
Schedule of Investments [Line Items]  
Carrying value, after allowance for credit loss $ 628
60% to 79% | Weighted Average  
Schedule of Investments [Line Items]  
Average Debt Service Coverage Ratio 1.71
80% to 100%  
Schedule of Investments [Line Items]  
Carrying value, after allowance for credit loss $ 163
80% to 100% | Weighted Average  
Schedule of Investments [Line Items]  
Average Debt Service Coverage Ratio 0.88
v3.25.1
Investments - Commercial Mortgage Loans, Including Disposal Groups (Details) - Real Estate Loan - Commercial Portfolio Segment
$ in Millions
 3 Months Ended
Mar. 31, 2024
Dec. 31, 2024
USD ($)
Schedule of Investments [Line Items]    
Carrying value, after allowance for credit loss, including assets held for sale   $ 1,351
Weighted Average    
Schedule of Investments [Line Items]    
Average Debt Service Coverage Ratio, including assets held for sale 1.70  
Average Loan-to-Value Ratio, including assets held for sale 0.69  
Below 60%    
Schedule of Investments [Line Items]    
Carrying value, after allowance for credit loss, including assets held for sale   547
Below 60% | Weighted Average    
Schedule of Investments [Line Items]    
Average Debt Service Coverage Ratio, including assets held for sale 2.07  
60% to 79%    
Schedule of Investments [Line Items]    
Carrying value, after allowance for credit loss, including assets held for sale   595
60% to 79% | Weighted Average    
Schedule of Investments [Line Items]    
Average Debt Service Coverage Ratio, including assets held for sale 1.83  
80% to 100%    
Schedule of Investments [Line Items]    
Carrying value, after allowance for credit loss, including assets held for sale   $ 209
80% to 100% | Weighted Average    
Schedule of Investments [Line Items]    
Average Debt Service Coverage Ratio, including assets held for sale 0.51  
v3.25.1
Investments - Other Long-Term Investments (Details) - USD ($)
$ in Millions
Mar. 31, 2025
Dec. 31, 2024
Schedule of Investments [Line Items]    
Other long-term investments $ 4,685  
Real estate investments    
Schedule of Investments [Line Items]    
Other long-term investments 1,808 $ 1,763
Securities partnerships    
Schedule of Investments [Line Items]    
Other long-term investments 2,660 $ 2,587
Other    
Schedule of Investments [Line Items]    
Other long-term investments $ 217  
v3.25.1
Investments - Other Long-Term Investments, Including Disposal Groups (Details)
$ in Millions
Dec. 31, 2024
USD ($)
Schedule of Investments [Line Items]  
Other long term investments, including held for sale assets $ 4,576
Other  
Schedule of Investments [Line Items]  
Other long term investments, including held for sale assets $ 226
v3.25.1
Investments - Derivative Financial Instruments (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Derivative [Line Items]      
Derivative gain (loss) reclassified from other comprehensive income into shareholders' net income  
Derivative gain (loss) recognized in other comprehensive income  
Derivative gain (loss) recognized in the income statement  
Designated as Hedging Instrument | Fair Value Hedging | Fair value hedge - Interest rate swap contracts      
Derivative [Line Items]      
Notional Value $ 3,000   $ 2,700
v3.25.1
Investments - Investment Gains and Losses (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Investments [Abstract]    
Net investment losses, before income taxes $ (2) $ (1,836)
v3.25.1
Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value (Details) - USD ($)
$ in Millions
Mar. 31, 2025
Dec. 31, 2024
Financial assets at fair value:    
Equity securities $ 38 $ 37
Recurring    
Financial assets at fair value:    
Debt Securities 8,215  
Equity securities 38 37
Short-term investments 196 170
Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring    
Financial assets at fair value:    
Debt Securities 104  
Equity securities 1 1
Short-term investments 0 0
Significant Other Observable Inputs (Level 2) | Recurring    
Financial assets at fair value:    
Debt Securities 7,738  
Equity securities 37 36
Short-term investments 196 170
Significant Unobservable Inputs (Level 3) | Recurring    
Financial assets at fair value:    
Debt Securities 373  
Equity securities 0 0
Short-term investments 0 0
Federal government and agency | Recurring    
Financial assets at fair value:    
Debt Securities 223  
Federal government and agency | Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring    
Financial assets at fair value:    
Debt Securities 104  
Federal government and agency | Significant Other Observable Inputs (Level 2) | Recurring    
Financial assets at fair value:    
Debt Securities 119  
Federal government and agency | Significant Unobservable Inputs (Level 3) | Recurring    
Financial assets at fair value:    
Debt Securities 0  
State and local government | Recurring    
Financial assets at fair value:    
Debt Securities 25  
State and local government | Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring    
Financial assets at fair value:    
Debt Securities 0  
State and local government | Significant Other Observable Inputs (Level 2) | Recurring    
Financial assets at fair value:    
Debt Securities 25  
State and local government | Significant Unobservable Inputs (Level 3) | Recurring    
Financial assets at fair value:    
Debt Securities 0  
Foreign government | Recurring    
Financial assets at fair value:    
Debt Securities 358  
Foreign government | Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring    
Financial assets at fair value:    
Debt Securities 0  
Foreign government | Significant Other Observable Inputs (Level 2) | Recurring    
Financial assets at fair value:    
Debt Securities 358  
Foreign government | Significant Unobservable Inputs (Level 3) | Recurring    
Financial assets at fair value:    
Debt Securities 0  
Corporate | Recurring    
Financial assets at fair value:    
Debt Securities 7,280  
Corporate | Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring    
Financial assets at fair value:    
Debt Securities 0  
Corporate | Significant Other Observable Inputs (Level 2) | Recurring    
Financial assets at fair value:    
Debt Securities 6,951  
Corporate | Significant Unobservable Inputs (Level 3) | Recurring    
Financial assets at fair value:    
Debt Securities 329  
Mortgage and other asset-backed | Recurring    
Financial assets at fair value:    
Debt Securities 329  
Mortgage and other asset-backed | Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring    
Financial assets at fair value:    
Debt Securities 0  
Mortgage and other asset-backed | Significant Other Observable Inputs (Level 2) | Recurring    
Financial assets at fair value:    
Debt Securities 285  
Mortgage and other asset-backed | Significant Unobservable Inputs (Level 3) | Recurring    
Financial assets at fair value:    
Debt Securities 44  
Derivatives | Recurring    
Financial assets at fair value:    
Derivative assets 153 168
Liabilities, Fair Value Disclosure [Abstract]    
Derivative liabilities 2 1
Derivatives | Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring    
Financial assets at fair value:    
Derivative assets 0 0
Liabilities, Fair Value Disclosure [Abstract]    
Derivative liabilities 0 0
Derivatives | Significant Other Observable Inputs (Level 2) | Recurring    
Financial assets at fair value:    
Derivative assets 153 168
Liabilities, Fair Value Disclosure [Abstract]    
Derivative liabilities 2 1
Derivatives | Significant Unobservable Inputs (Level 3) | Recurring    
Financial assets at fair value:    
Derivative assets 0 0
Liabilities, Fair Value Disclosure [Abstract]    
Derivative liabilities $ 0 $ 0
v3.25.1
Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value, Including Disposal Groups (Details) - Recurring
$ in Millions
Dec. 31, 2024
USD ($)
Financial assets at fair value:  
Debt Securities, including held for sale assets $ 9,423
Quoted Prices in Active Markets for Identical Assets (Level 1)  
Financial assets at fair value:  
Debt Securities, including held for sale assets 165
Significant Other Observable Inputs (Level 2)  
Financial assets at fair value:  
Debt Securities, including held for sale assets 8,841
Significant Unobservable Inputs (Level 3)  
Financial assets at fair value:  
Debt Securities, including held for sale assets 417
Federal government and agency  
Financial assets at fair value:  
Debt Securities, including held for sale assets 281
Federal government and agency | Quoted Prices in Active Markets for Identical Assets (Level 1)  
Financial assets at fair value:  
Debt Securities, including held for sale assets 165
Federal government and agency | Significant Other Observable Inputs (Level 2)  
Financial assets at fair value:  
Debt Securities, including held for sale assets 116
Federal government and agency | Significant Unobservable Inputs (Level 3)  
Financial assets at fair value:  
Debt Securities, including held for sale assets 0
State and local government  
Financial assets at fair value:  
Debt Securities, including held for sale assets 37
State and local government | Quoted Prices in Active Markets for Identical Assets (Level 1)  
Financial assets at fair value:  
Debt Securities, including held for sale assets 0
State and local government | Significant Other Observable Inputs (Level 2)  
Financial assets at fair value:  
Debt Securities, including held for sale assets 37
State and local government | Significant Unobservable Inputs (Level 3)  
Financial assets at fair value:  
Debt Securities, including held for sale assets 0
Foreign government  
Financial assets at fair value:  
Debt Securities, including held for sale assets 344
Foreign government | Quoted Prices in Active Markets for Identical Assets (Level 1)  
Financial assets at fair value:  
Debt Securities, including held for sale assets 0
Foreign government | Significant Other Observable Inputs (Level 2)  
Financial assets at fair value:  
Debt Securities, including held for sale assets 344
Foreign government | Significant Unobservable Inputs (Level 3)  
Financial assets at fair value:  
Debt Securities, including held for sale assets 0
Corporate  
Financial assets at fair value:  
Debt Securities, including held for sale assets 8,423
Corporate | Quoted Prices in Active Markets for Identical Assets (Level 1)  
Financial assets at fair value:  
Debt Securities, including held for sale assets 0
Corporate | Significant Other Observable Inputs (Level 2)  
Financial assets at fair value:  
Debt Securities, including held for sale assets 8,049
Corporate | Significant Unobservable Inputs (Level 3)  
Financial assets at fair value:  
Debt Securities, including held for sale assets 374
Mortgage and other asset-backed  
Financial assets at fair value:  
Debt Securities, including held for sale assets 338
Mortgage and other asset-backed | Quoted Prices in Active Markets for Identical Assets (Level 1)  
Financial assets at fair value:  
Debt Securities, including held for sale assets 0
Mortgage and other asset-backed | Significant Other Observable Inputs (Level 2)  
Financial assets at fair value:  
Debt Securities, including held for sale assets 295
Mortgage and other asset-backed | Significant Unobservable Inputs (Level 3)  
Financial assets at fair value:  
Debt Securities, including held for sale assets $ 43
v3.25.1
Fair Value Measurements - Quantitative Information About Unobservable Inputs (Details) - Recurring - Significant Unobservable Inputs (Level 3)
$ in Millions
Mar. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Debt securities    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Fair Value $ 373  
Corporate | Securities Priced by the Company    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Fair Value $ 329  
Corporate | Securities Priced by the Company | Minimum | Liquidity    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Unobservable Adjustment 0.0005  
Corporate | Securities Priced by the Company | Maximum | Liquidity    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Unobservable Adjustment 0.1475  
Corporate | Securities Priced by the Company | Weighted Average | Liquidity    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Unobservable Adjustment 0.0300  
Mortgage and other asset-backed securities | Securities Priced by the Company    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Fair Value $ 44  
Mortgage and other asset-backed securities | Securities Priced by the Company | Minimum | Liquidity    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Unobservable Adjustment 0.0105  
Mortgage and other asset-backed securities | Securities Priced by the Company | Maximum | Liquidity    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Unobservable Adjustment 0.0575  
Mortgage and other asset-backed securities | Securities Priced by the Company | Weighted Average | Liquidity    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Unobservable Adjustment 0.0290  
Other debt securities    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Fair Value $ 0 $ 1
v3.25.1
Fair Value Measurements - Quantitative Information About Unobservable Inputs, Including Disposal Groups (Details) - Recurring - Significant Unobservable Inputs (Level 3)
$ in Millions
Dec. 31, 2024
USD ($)
Debt securities  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Fair Value, including held for sale assets $ 417
Corporate | Securities Priced by the Company  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Fair Value, including held for sale assets $ 373
Corporate | Securities Priced by the Company | Minimum | Liquidity  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Unobservable Adjustment, including held for sale assets 0.0060
Corporate | Securities Priced by the Company | Maximum | Liquidity  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Unobservable Adjustment, including held for sale assets 0.1520
Corporate | Securities Priced by the Company | Weighted Average | Liquidity  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Unobservable Adjustment, including held for sale assets 0.0370
Mortgage and other asset-backed securities | Securities Priced by the Company  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Fair Value, including held for sale assets $ 43
Mortgage and other asset-backed securities | Securities Priced by the Company | Minimum | Liquidity  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Unobservable Adjustment, including held for sale assets 0.0100
Mortgage and other asset-backed securities | Securities Priced by the Company | Maximum | Liquidity  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Unobservable Adjustment, including held for sale assets 0.0550
Mortgage and other asset-backed securities | Securities Priced by the Company | Weighted Average | Liquidity  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Unobservable Adjustment, including held for sale assets 0.0280
v3.25.1
Fair Value Measurements - Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Transfers into / (out of) Level 3    
Change in unrealized gain or (loss) included in Other comprehensive loss for assets held at the end of the reporting period $ 3 $ (4)
Debt securities    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Beginning balance, including held for sale assets 417 447
Losses included in Shareholders' net income (loss) (10) (21)
Gains (losses) included in Other comprehensive loss 7 (3)
Purchases, sales and settlements    
Purchases 2 0
Settlements (31) (14)
Total purchases, sales and settlements (29) (14)
Transfers into / (out of) Level 3    
Transfers into Level 3 18 16
Transfers out of Level 3 (30) (3)
Total transfers into / (out of) Level 3 (12) 13
Ending balance 373  
Ending balance, including held for sale assets   422
Total losses included in Shareholders' net income (loss) attributable to instruments held at the reporting date $ (13) $ (21)
v3.25.1
Fair Value Measurements - Separate Accounts (Details) - USD ($)
$ in Millions
Mar. 31, 2025
Dec. 31, 2024
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Guaranteed separate accounts $ 555 $ 576
Non-guaranteed separate accounts 6,089 6,070
Subtotal 6,644 6,646
Non-guaranteed separate accounts priced at NAV as a practical expedient 633 632
Separate account assets 7,277 7,278
Pension Plans    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Non-guaranteed separate accounts 3,800 3,800
Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Guaranteed separate accounts 227 231
Non-guaranteed separate accounts 275 267
Subtotal 502 498
Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Guaranteed separate accounts 328 345
Non-guaranteed separate accounts 5,559 5,575
Subtotal 5,887 5,920
Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Guaranteed separate accounts 0 0
Non-guaranteed separate accounts 255 228
Subtotal 255 228
Significant Unobservable Inputs (Level 3) | Pension Plans    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Non-guaranteed separate accounts $ 200 $ 200
v3.25.1
Fair Value Measurements - Assets and Liabilities Measured at Fair Value under Certain Conditions (Details) - USD ($)
$ in Millions
 2 Months Ended 3 Months Ended
Mar. 31, 2024
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]        
Equity Securities without Readily Determinable Fair Value, Amount   $ 521   $ 524
Impairments requiring certain assets and liabilities to be measured at fair value      
Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount    
Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount    
VillageMD        
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]        
Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount $ 1,800      
v3.25.1
Fair Value Measurements - Fair Value Disclosures for Financial Instruments Not Carried at Fair Value (Details) - USD ($)
$ in Millions
Mar. 31, 2025
Dec. 31, 2024
Fair Value | Significant Other Observable Inputs (Level 2)    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Long-term debt, including current maturities, excluding finance leases $ 28,149 $ 28,392
Fair Value | Significant Unobservable Inputs (Level 3)    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Commercial mortgage loans 1,228 1,256
Carrying Value    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Commercial mortgage loans 1,294 1,351
Long-term debt, including current maturities, excluding finance leases $ 30,371 $ 31,008
v3.25.1
Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]    
Balance $ 41,243 $ 46,244
Other comprehensive income (loss) (249) (460)
Balance 40,414 41,350
AOCI Attributable to Parent    
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]    
Balance (2,341) (1,864)
Other comprehensive income (loss) (249) (460)
Balance (2,590) (2,324)
Other Comprehensive Income (Loss), Tax [Abstract]    
Other Comprehensive Income (Loss), Tax 82 141
Securities and Derivatives    
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]    
Balance 832 171
Other comprehensive income (loss) before reclassifications, after-tax (134) 104
Net amounts reclassified from AOCI to net income 34 17
Other comprehensive income (loss) (100) 121
Balance 732 292
Other Comprehensive Income (Loss), Tax [Abstract]    
Other comprehensive income (loss), before reclassifications, tax 49 (39)
Reclassification adjustment, tax (9) (5)
Net long-duration insurance and contractholder liabilities measurement adjustments    
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]    
Balance (2,038) (971)
Other comprehensive income (loss) (168) (560)
Balance (2,206) (1,531)
Change in discount rate for certain long-duration liabilities    
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]    
Other comprehensive income (loss) before reclassifications, after-tax (108) (546)
Net amounts reclassified from AOCI to net income (56) 0
Other comprehensive income (loss) (164) (546)
Other Comprehensive Income (Loss), Tax [Abstract]    
Other comprehensive income (loss), before reclassifications, tax 33 186
Reclassification adjustment, tax 16 0
Other Comprehensive Income (Loss), Tax 49 186
Change in instrument-specific credit risk for market risk benefits    
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]    
Other comprehensive income (loss) before reclassifications, after-tax (4) (14)
Other Comprehensive Income (Loss), Tax [Abstract]    
Other comprehensive income (loss), before reclassifications, tax 1 4
Translation of foreign currencies    
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]    
Balance (198) (149)
Other comprehensive income (loss) before reclassifications, after-tax 13 (26)
Balance (185) (175)
Other Comprehensive Income (Loss), Tax [Abstract]    
Other comprehensive income (loss), before reclassifications, tax (6) (2)
Postretirement benefits liability    
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]    
Balance (937) (915)
Net amounts reclassified from AOCI to net income 6 5
Balance (931) (910)
Other Comprehensive Income (Loss), Tax [Abstract]    
Reclassification adjustment, tax $ (2) $ (3)
v3.25.1
Strategic Optimization Program (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Restructuring Reserve [Roll Forward]    
Restructuring costs $ 215 $ 0
Strategic optimization program costs, after-tax 163 $ 0
Employee severance and other restructuring    
Restructuring Reserve [Roll Forward]    
Restructuring costs $ 198  
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration] Selling, general and administrative expenses  
Strategic optimization program costs, after-tax $ 150  
Employee severance    
Restructuring Reserve [Roll Forward]    
Restructuring Reserve, Beginning Balance 0  
Restructuring costs 171  
Payments (10)  
Restructuring Reserve, Ending Balance $ 161  
v3.25.1
Income Taxes - Narrative (Details)
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Income Tax Disclosure [Abstract]    
Consolidated effective tax rate 14.50% 368.40%
v3.25.1
Income Taxes - Valuation Allowances (Details) - USD ($)
$ in Millions
Mar. 31, 2025
Mar. 31, 2024
Valuation Allowance [Line Items]    
Deferred tax assets, impairment of equity securities and other unrealized investment losses. $ 856  
Impairment of equity securities | Equity securities    
Valuation Allowance [Line Items]    
Deferred tax assets, valuation allowance $ 636 $ 427
v3.25.1
Contingencies and Other Matters (Details)
 3 Months Ended
Mar. 31, 2025
USD ($)
Guaranty Fund Assessments  
Commitments And Contingencies [Line Items]  
Loss contingency accrual provision
Indemnification obligations  
Commitments And Contingencies [Line Items]  
Liability for guarantees 0
Retiree and Life Insurance Benefits | Financial Guarantees  
Commitments And Contingencies [Line Items]  
Maximum guarantee exposure 410,000,000
Assets maintained by employers (minimum) 410,000,000
Liability for guarantees $ 0
v3.25.1
Segment Information - Special Item Charges (Benefits) (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Pre-tax    
Integration and transaction-related costs (Selling, general and administrative expenses) $ 216 $ 37
Strategic optimization program (primarily Selling, general and administrative expenses) 215 0
Deferred tax expenses, net (Income taxes, less amount attributable to noncontrolling interests) 0 0
(Gain) loss on sale of businesses (41) 19
Total impact from special items 390 56
After-tax    
Integration and transaction-related costs (Selling, general and administrative expenses) 164 29
Strategic optimization program (primarily Selling, general and administrative expenses) 163 0
Deferred tax expenses, net (Income taxes, less amount attributable to noncontrolling interests) 17 17
(Gain) loss on sale of businesses (115) (43)
Total impact from special items $ 229 $ 3
v3.25.1
Segment Information - Summarized Segment Financial Information (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Segment Reporting Information [Line Items]    
Revenues from customers $ 65,264 $ 56,965
Net investment income (loss) 238 290
TOTAL REVENUES 65,502 57,255
Net investment results from certain equity method investments (50) (8)
Adjusted revenues 65,452 57,247
Pharmacy and other service costs 48,398 41,431
Medical costs and other benefit expenses 10,498 9,440
Interest expense and other (362) (322)
Pre-tax adjusted income (loss) from operations 2,310 2,309
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 1,648 79
Pre-tax adjustments to reconcile to adjusted income from operations    
(Income) loss attributable to noncontrolling interests (102) (77)
Net realized investment (gains) losses (48) 1,828
Amortization of acquired intangible assets 422 423
Special items    
Integration and transaction-related costs 216 37
Restructuring costs 215 0
(Gain) loss on sale of businesses (41) 19
Deferred tax expenses 0 0
Pre-tax adjusted income (loss) from operations 2,310 2,309
Depreciation and amortization 674 741
Evernorth Health Services    
Segment Reporting Information [Line Items]    
Revenues from customers 52,002 44,886
Cigna Healthcare    
Segment Reporting Information [Line Items]    
Revenues from customers 13,168 12,012
Other Operations    
Segment Reporting Information [Line Items]    
Revenues from customers 94 66
Operating Segments | Evernorth Health Services    
Segment Reporting Information [Line Items]    
Net investment income (loss) 31 59
TOTAL REVENUES 53,681 46,226
Net investment results from certain equity method investments 0 0
Adjusted revenues 53,681 46,226
Pharmacy and other service costs 51,121 43,838
Medical costs and other benefit expenses 0 0
Selling, general and administrative expenses 1,024 951
Interest expense and other 0 0
Less: Income attributable to noncontrolling interests 102 77
Pre-tax adjusted income (loss) from operations 1,434 1,360
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 1,108 (436)
Pre-tax adjustments to reconcile to adjusted income from operations    
(Income) loss attributable to noncontrolling interests (102) (77)
Net realized investment (gains) losses (4) 1,456
Amortization of acquired intangible assets 415 417
Special items    
Integration and transaction-related costs 0 0
Restructuring costs 21  
(Gain) loss on sale of businesses (4) 0
Pre-tax adjusted income (loss) from operations 1,434 1,360
Depreciation and amortization 584 606
Operating Segments | Cigna Healthcare    
Segment Reporting Information [Line Items]    
Net investment income (loss) 133 149
TOTAL REVENUES 14,532 13,285
Net investment results from certain equity method investments (50) (8)
Adjusted revenues 14,482 13,277
Pharmacy and other service costs 0 0
Medical costs and other benefit expenses 10,385 9,219
Selling, general and administrative expenses 2,812 2,720
Interest expense and other 2 2
Less: Income attributable to noncontrolling interests 0 0
Pre-tax adjusted income (loss) from operations 1,287 1,340
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 1,364 943
Pre-tax adjustments to reconcile to adjusted income from operations    
(Income) loss attributable to noncontrolling interests 0 0
Net realized investment (gains) losses (47) 372
Amortization of acquired intangible assets 7 6
Special items    
Integration and transaction-related costs 0 0
Restructuring costs 0  
(Gain) loss on sale of businesses (37) 19
Pre-tax adjusted income (loss) from operations 1,287 1,340
Depreciation and amortization 83 124
Operating Segments | Other Operations    
Segment Reporting Information [Line Items]    
Net investment income (loss) 69 75
TOTAL REVENUES 175 166
Net investment results from certain equity method investments 0 0
Adjusted revenues 175 166
Pre-tax adjusted income (loss) from operations 0 18
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (20) 18
Pre-tax adjustments to reconcile to adjusted income from operations    
(Income) loss attributable to noncontrolling interests 0 0
Net realized investment (gains) losses 3 0
Amortization of acquired intangible assets 0 0
Special items    
Integration and transaction-related costs 0 0
Restructuring costs 17  
(Gain) loss on sale of businesses 0 0
Pre-tax adjusted income (loss) from operations 0 18
Depreciation and amortization 2 1
Corporate and Eliminations    
Segment Reporting Information [Line Items]    
TOTAL REVENUES (2,886) (2,422)
Adjusted revenues (2,886) (2,422)
Special items    
Depreciation and amortization 5 10
Corporate    
Segment Reporting Information [Line Items]    
Revenues from customers 0 1
Net investment income (loss) 5 7
Net investment results from certain equity method investments 0 0
Pre-tax adjusted income (loss) from operations (411) (409)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (804) (446)
Pre-tax adjustments to reconcile to adjusted income from operations    
(Income) loss attributable to noncontrolling interests 0 0
Net realized investment (gains) losses 0 0
Amortization of acquired intangible assets 0 0
Special items    
Integration and transaction-related costs 216 37
Restructuring costs 177  
(Gain) loss on sale of businesses 0 0
Pre-tax adjusted income (loss) from operations (411) (409)
Intersegment Eliminations    
Segment Reporting Information [Line Items]    
Revenues from customers (2,891) (2,430)
Intersegment Eliminations | Evernorth Health Services    
Segment Reporting Information [Line Items]    
Revenues from customers (1,648) (1,281)
Intersegment Eliminations | Cigna Healthcare    
Segment Reporting Information [Line Items]    
Revenues from customers (1,231) (1,124)
Intersegment Eliminations | Other Operations    
Segment Reporting Information [Line Items]    
Revenues from customers $ (12) $ (25)
v3.25.1
Segment Information - Revenue from External Customers (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Revenue from External Customer [Line Items]    
Premiums $ 12,736 $ 11,603
Total revenues from external customers 65,264 56,965
Pharmacy revenues    
Revenue from External Customer [Line Items]    
Revenue from contract with customer 48,633 42,036
Service    
Revenue from External Customer [Line Items]    
Revenue from contract with customer 3,895 3,326
Service, Fees And Other Revenues [Member]    
Revenue from External Customer [Line Items]    
Revenue from contract with customer 3,895 3,326
Evernorth Health Services    
Revenue from External Customer [Line Items]    
Total revenues from external customers 52,002 44,886
Cigna Healthcare    
Revenue from External Customer [Line Items]    
Total revenues from external customers 13,168 12,012
Other Operations    
Revenue from External Customer [Line Items]    
Total revenues from external customers 94 66
Operating Segments | Other revenue    
Revenue from External Customer [Line Items]    
Revenue from contract with customer 162 90
Operating Segments | Evernorth Health Services | Pharmacy revenues    
Revenue from External Customer [Line Items]    
Revenue from contract with customer 50,226 43,170
Operating Segments | Evernorth Health Services | Network revenues    
Revenue from External Customer [Line Items]    
Revenue from contract with customer 28,212 24,166
Operating Segments | Evernorth Health Services | Home delivery and specialty revenues    
Revenue from External Customer [Line Items]    
Revenue from contract with customer 18,937 16,458
Operating Segments | Evernorth Health Services | Other revenues    
Revenue from External Customer [Line Items]    
Revenue from contract with customer 3,077 2,546
Operating Segments | Evernorth Health Services | Service, Fees And Other Revenues [Member]    
Revenue from External Customer [Line Items]    
Revenue from contract with customer 3,424 2,997
Operating Segments | Cigna Healthcare    
Revenue from External Customer [Line Items]    
Premiums 12,628 11,531
Operating Segments | Cigna Healthcare | Service, Fees And Other Revenues [Member]    
Revenue from External Customer [Line Items]    
Revenue from contract with customer 1,771 1,605
Operating Segments | Cigna Healthcare | U.S. Healthcare    
Revenue from External Customer [Line Items]    
Premiums 11,650 10,646
Operating Segments | Cigna Healthcare | U.S. Healthcare | Employer insured    
Revenue from External Customer [Line Items]    
Premiums 4,688 4,393
Operating Segments | Cigna Healthcare | U.S. Healthcare | Medicare Advantage    
Revenue from External Customer [Line Items]    
Premiums 2,363 2,287
Operating Segments | Cigna Healthcare | U.S. Healthcare | Stop loss    
Revenue from External Customer [Line Items]    
Premiums 1,868 1,668
Operating Segments | Cigna Healthcare | U.S. Healthcare | Individual and Family Plans    
Revenue from External Customer [Line Items]    
Premiums 859 1,040
Operating Segments | Cigna Healthcare | U.S. Healthcare | Other    
Revenue from External Customer [Line Items]    
Premiums 1,872 1,258
Operating Segments | Cigna Healthcare | International Health    
Revenue from External Customer [Line Items]    
Premiums 978 885
Operating Segments | Other Operations    
Revenue from External Customer [Line Items]    
Premiums 81 48
Operating Segments | Other Operations | Pharmacy revenues    
Revenue from External Customer [Line Items]    
Revenue from contract with customer 13 17
Operating Segments | Other Operations | Service, Fees And Other Revenues [Member]    
Revenue from External Customer [Line Items]    
Revenue from contract with customer 12 26
Corporate and Eliminations    
Revenue from External Customer [Line Items]    
Premiums 27 24
Corporate and Eliminations | Pharmacy revenues    
Revenue from External Customer [Line Items]    
Revenue from contract with customer (1,606) (1,151)
Corporate and Eliminations | Service, Fees And Other Revenues [Member]    
Revenue from External Customer [Line Items]    
Revenue from contract with customer (1,312) (1,302)
Corporate    
Revenue from External Customer [Line Items]    
Total revenues from external customers 0 1
Intersegment Eliminations    
Revenue from External Customer [Line Items]    
Total revenues from external customers (2,891) (2,430)
Intersegment Eliminations | Evernorth Health Services    
Revenue from External Customer [Line Items]    
Total revenues from external customers (1,648) (1,281)
Intersegment Eliminations | Cigna Healthcare    
Revenue from External Customer [Line Items]    
Total revenues from external customers (1,231) (1,124)
Intersegment Eliminations | Other Operations    
Revenue from External Customer [Line Items]    
Total revenues from external customers $ (12) $ (25)
v3.25.1
Segment Information - Financial and Performance Guarantees (Details) - USD ($)
$ in Billions
Mar. 31, 2025
Dec. 31, 2024
Evernorth Health Services | Financial and performance guarantees    
Loss Contingencies [Line Items]    
Guarantee liability $ 1.9 $ 1.9